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ABSTRACT

Tissue engineering holds great promise for treatment of valvular diseases.
Scaffolds for engineered heart valves must function immediately after implantation, but
must also permit repopulation with autologous host cells and facilitate gradual
remodeling.
Native aortic heart valves are composed of three layers, i.e. two strong external
fibrous layers (ventricularis and fibrosa) separated by a central, highly hydrated
spongiosa. The fibrous layers provide strength and resilience while the spongiosa layer
facilitates shearing of the external layers. Our working hypothesis is that partially crosslinked collagen scaffolds that closely mimic the layered histo-architecture of the native
valve would fulfill these requirements. To test this hypothesis we have developed heart
valve-shaped tri-layered constructs based on collagen, the major structural component in
natural heart valves. We describe here the development and characterization of two types
of scaffolds, namely the fibrous scaffolds prepared from decellularized porcine
pericardium and spongiosa scaffolds from elastase-treated decellularized pulmonary
arteries. Fibrous scaffolds were cross-linked with penta galloyl glucose (PGG) to control
remodeling. In order to assemble the scaffolds into a 3D valve structure and form the trilayered leaflets, we developed a bio-adhesive consisting of mixtures of bovine serum
albumin and glutaraldehyde (BTglue) and an efficient method to reduce aldehyde
toxicity. Glued fibrous scaffolds were tested in vitro for biocompatibility (cell culture)
and degradation (collagenase and proteinase K digestion). Tri-layered constructs were
also tested for in vivo biocompatibility, cell repopulation and calcification.
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In current studies, we have confirmed that scaffolds glued with BTglue were noncytotoxic, with living cells spread across the entire surface of the BT-glue test area and
cells growing directly on to the glued surfaces. With the long term aim of our studies
being to create anatomically correct scaffolds to be used as personalized constructs for
heart valve tissue engineering, we created silicone molds from porcine aortic heart valves
and then modeled decellularized porcine pericardium into anatomically correct scaffolds.
After drying them in their molds, the scaffolds have acquired the shape of the aortic valve
which could then be preserved by exposure to PGG. After inserting decellularized
pulmonary artery between the fibrous scaffolds to mimic the spongiosa layer,
functionality testing of the heart valve-shaped scaffolds in a custom-made bioreactor
showed good leaflet coaptation upon closure and good opening characteristics. Stem cellseeded scaffolds also showed cellular differentiation into valvular interstitial-like cells
(VICs) in similar bioreactor studies.
Future studies are needed to perfect the assembly process of the tri-layered
construct. Additionally, further evaluation of stem cell differentiation is needed to
confirm the presence of VICs in the aortic valve. If successful, there is potential that this
approach of layering collagenous scaffolds into tri-layered constructs that mimic the
native structure of the native aortic heart valve holds promise for the future of heart valve
tissue engineering.
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CHAPTER 1
INTRODUCTION

Replacement or regeneration of aortic heart valves, exquisite examples of
durability, design and adaptability, has challenged engineers and surgeons for the last 50
years. Current treatment of valvular pathology is surgical replacement with mechanical
valves, valves made from biological tissues or human allografts, but these devices have
functional limitations, such as the need for life-long anticoagulation, risks of developing
endocarditis and propensity to degenerate and calcify [1].
Native aortic valve leaflets are complex structures composed of external layers,
the fibrosa (composed of collagen) on the arterial aspect and the ventricularis (collagen
and elastin) on the ventricular aspect. The fibrous layers are sustained internally by a
highly hydrated central spongiosa layer (rich in proteoglycans) that serves as a cushion
material to mediate deformations of the fibrous layers, allows shearing between the outer
layers and absorbs compressive forces during valve function [2-4]. Lack of a buffering
layer results in large shear stress and tissue buckling when subjected to bending [5].
The predominant cell populations in heart valves are valvular interstitial cells
(VICs) which continuously secrete matrix components as well as matrix degrading
enzymes that mediate remodeling [6-8]. VICs exhibit a dynamic phenotypic spectrum
ranging from quiescent fibroblast-like cells (characterized by expression of vimentin and
low expression of alpha-smooth muscle cell actin), to activated VICs, assimilated as
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myofibroblasts (characterized by proliferation, migration and high expression of alphasmooth muscle cell actin) [1, 9-12].
Tissue engineering, the science of combining scaffolds, cells and specific signals
to create living tissues is feasible and holds great promise for treatment of heart valve
disease [13]. Two main strategies have been developed in recent years. The first is based
on use of decellularized porcine valves followed by in vitro or in vivo repopulation with
cells of interest. Despite their excellent mechanics, acellular valves are very dense and
thus difficult to repopulate with desired cells. The second approach employs cell seeded
polymeric biodegradable matrices [14] or scaffolds built from fibrin [15]. While
polymeric and fibrin-based scaffolds have shown very promising results, these
degradable matrices have insufficient strength to withstand arterial pressures immediately
after implantation.
Our novel strategy relies on use of stabilized collagen scaffolds that mimic the
natural valve fibrous layers, based on decellularized porcine pericardium [16] and
delicate, highly hydrated porous collagen scaffolds to be used as the middle spongiosa
layer. Chemically stabilized pericardium has outstanding mechanical properties, a good
record of implantation in humans as valves, and as reconstructive surgery biomaterial
patches in other organs [17-23]. To reduce scaffold biodegradation, we have also
investigated the use of penta-galloyl glucose (PGG), a naturally derived collagen-binding
polyphenol [16, 24]. No reports to date have documented the use of PGG-stabilized
acellular pericardium for construction of tissue engineered heart valves. Since the
xenoantigen Gal1-3Gal (Gal), is responsible for rejection of vascularized organ
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transplants we are also paying special attention to Gal detection in decellularized
scaffolds [25-29].
Recognizing the outstanding mechanical performance of natural valve
homografts, the vital importance of the three leaflet layers [30], and the need for
reconstruction of the physiologic valve design, we developed five building blocks for this
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) trilayered constructs that mimic the native heart valve histo-architecture, d) autologous
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical
cues to induce stem cell differentiation into valvular cells capable of maintaining matrix
homeostasis.
Cell sourcing for seeding heart valve scaffolds includes differentiated cells
(smooth muscle cells, fibroblasts) and mesenchymal or embryonic stem cells [31, 32].
Other cell sources include peripheral blood and human umbilical cord blood [33]. Upon
biochemical and/or mechanical stimulation, most of these cells express markers of
quiescent VICs such as vimentin, among others [34]. We have chosen to investigate bone
marrow-derived stem cells as a possible source for stem cells.
To assemble the 3D heart valve structures we developed and implemented the use
of biological adhesives for tissue engineering purposes. At a minimum, these adhesives
need to exhibit adequate bond strength and elasticity, long term stability and
biocompatibility. We chose to implement a modified albumin/glutaraldehyde adhesive
for the construction of living heart valves. We describe the development and extensive
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characteristics of novel scaffolds to be used as the acellular fibrous pericardial scaffolds
used to mimic the fibrosa and ventricularis, the amorphous pulmonary artery scaffolds to
be used as the spongiosa layer, and utilization of a biological glue to assemble the trilayered constructs. We also show that bioreactor conditioning of stem cell-seeded trilayered valves induced differentiation into VIC-like cells.
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CHAPTER 2
LITERATURE REVIEW

2.1

Physiology of Native Heart Valves
The heart provides unidirectional flow of blood through the body’s circulatory

system (Figure 2.1). This is due to the superb structure of natural heart valves. The four
valves of the heart are excellent examples of optimum durability, design, and
adaptability.

Figure 2.1: The four valves of the heart in systole [1]
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The right side of the heart consists of the right atrium, which collects
deoxygenated blood from the circulatory system, and the right ventricle, which pumps
this blood to the lungs to be oxygenated. Between these two chambers is the tricuspid
valve. anchored in its insertions into the annulus by thread-like chordae tendinae [2]. It
functions to ensure that the blood within the right ventricle is pumped to the lungs rather
than back into the right atrium during systole. The blood then moves through the
pulmonary valve, or semilunar valve, which prevents flow of blood from the pulmonary
trunk back into the right ventricle while the ventricle fills during diastole.
The left side of the heart has a similar structure to the right. Oxygenated blood
from the lungs arrives at the left atrium from the pulmonary vein. During diastole, blood
flows through the mitral valve, into the left ventricle. The mitral valve is unique in that it
is composed of only two cusps, one anterior and one posterior [2]. Like the tricuspid
valves, it is associated with an extensive support system anchoring the cusps in place to
the base of the left ventricle via chordae tendinae [2]. As systole begins, intraventricular
pressure rises, closing the mitral valve and opening the aortic valve [3]. Like the
pulmonary and tricuspid valves, the aortic valve also has three cusps, lying at the origin
of the aorta. Blood flows out the aorta to feed the systemic circulation. As the ventricle
again begins to relax, the pressure increases to about 120 mmHg, and the aortic valve
snaps shut and the ventricle begins to fill. By the time the pressure in the aorta drops to
about 80 mmHg, the left ventricle has begun its contraction to pump another bolus of
blood and return the pressure to 120 mmHg [4].
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The left side of the heart must develop higher pressures than those on the right
side (Figure 2.2). This possibly contributes to the fact that heart valves on the left side of
the heart are most often affected by disease. Therefore, further discussion will focus on
the anatomy and physiology of the aortic valve, which is the most frequently
diseased and also most commonly replaced of the valves [5].

Figure 2.2: Blood flow through the heart and pressures in various segments [4]

2.1.1

Native Aortic Heart Valve Structure and Function
The aortic valve opens and closes approximately 103,000 times each day and

about 3.7 billion times in a lifetime [6]. In order to create an aortic valve replacement it is
essential to understand its function, anatomy and morphology of this valve.
The aortic valve is composed of three semilunar cusps (leaflets) attached to the
aortic valve ring, referred to as the annulus, at the commisures (Figure 2.3). Valve
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leaflets have few and only focal blood vessels, likely because valves cusps and leaflets
are thin enough to be nourished predominately by diffusion from blood [4]. The cusps are
cup-like, passive soft tissue structures attached to the wall of the aorta, in a region called
the aortic root. Because of its passive mechanism, the structure of the aortic valve must
open with minimal pressure differences between the ventricle and aorta [4]. During
closing, this same mechanism must prevent backflow by perfectly aligning the cusps,
which must have enough structural integrity to withstand systemic pressures. These
leaflets open during systole and press against the aortic root wall. When they snap close
at the start of diastole they meet to create a seal that can prevent backflow even with the
40 mmHg transvalvular pressure difference [4]. At this point, when the aortic valve is
closed, the aorta must distort to better comply with the increased pressures, thereby
decreasing the amount of stress on any one of the cusps.
In the aortic root, the cusps themselves are attached within the aortic sinuses, with
each cusp lying in direct apposition to three shallow indentations, known as the sinuses of
Valsalva [2] (Figure 2.3). These indentations in the aortic root change the fluid dynamics
of the valve significantly [7]. It is believed that the sinuses cause the formation of
vortices that aid in valve closure during retrograde blood flow [7]. Because two of these
sinuses give rise to coronary arteries, they have been conventionally named as the right
coronary, left coronary and noncoronary sinuses.
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Figure 2.3: (A) The three leaflets of the aortic valve [8] and (B) a depiction of an
individual leaflet and key landmarks [9].

2.1.2

Native Aortic Heart Valve Ultra-structure
Native heart valves maintain unidirectional blood flow via a dynamic structure

with several key characteristics: viability, sufficient strength to withstand repetitive and
substantial mechanical stress, and the ability to adapt and repair injury by connective
tissue remodeling [10]. The extreme amounts of cyclic fatigue that these tissues must
withstand in order to ensure optimum cardiac performance requires a highly organized
ultra-structure refined for these tasks. The four cardiac valves have microstructural
similarities, however the aortic valve best illustrates the central features and has served as
a standard by which to characterize the microstructural and cellular components of the
valves and how they relate to functional requirements [11]. Microscopically, the aortic
valve is composed of three distinct layers that adapt to mechanical changes and aid in
optimum opening and closing during the cardiac cycle: the fibrosa, the spongiosa, and
the ventricularis (Figure 2.4).
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Figure 2.4: (A) Cross-sectional view of the aortic valve representing the tri-layered
architecture of the native aortic valve [12]. (B) shows the normal interstitial cellularity
(cell nuclei: dark magenta) and the expected layered structure of the leaflet with the
ventricularis (v) as inflow side, spongiosa (s) as inner layer, followed by fibrosa (f) as
the outflow side (Movat-pentachrome stain for visualization of the major matrix proteins:
collagen, yellow; glycosaminoglycans, green-blue; elastin, black.) [10, 13].

The cuspal layer nearest the outflow surface (closest to the aorta) is known as the
fibrosa. It is composed primarily of densely packed, circumferentially aligned collagen
fibers that span the cusp from one commisure to another [11] (Figure 4, 5(A)). The
collagen fibers provide strength and stiffness to maintain coaptation during diastole,
when the cusp has maximal area. Thus, the collagen fibers carry the load that the cusps
are exposed to when the valve is closed and transfer this load to the aortic wall.
The middle layer, located between the fibrosa and the ventricularis, is the
spongiosa. It is composed mostly of glycosaminoglycans (GAGs) and collagen. The
collagen within this layer is crimped and densely packed with parallel arrangement to the
free edge of the cusp [14] (Figure 2.5). GAGs are high molecular weight linear
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polysaccharides composed of a series of repeating, negatively charged, hydrophilic
disaccharides [15]. The spongiosa has a gelatinous consistency, due in large part to the
hydrophilicity of the GAG molecules [15, 16]. It is thus easily deformed in the presence
of shear forces and cushions shock during the valve cycle and is not readily compressed.
This resistance to compression during bending aids in cuspal mechanics by preventing
buckling during flexion (systole), which could result in overall cuspal damage [17].
The final layer of the cusp is the ventricularis. It is located nearest the inflow
surface, adjacent to the left ventricle. The layer consists primarily of radially aligned
elastin fibers which, when relaxed, pull the collagen fibers of the fibrosa together,
forming the corrugations on the surface of the leaflet (Figure 2.4(B), 2.5(A)) [17]. In
general, the elastin in the valve forms an inter-connected matrix that binds the collagen
bundles, forming an elastin-collagen hybrid within a larger network of interconnected
collagen fibers [14]. The elastin extends during diastole and contracts in systole to
minimize cusp area, the net effect being to provide a dampening effect as the valve closes
and the cusp is stretched to coapt with its two neighboring leaflets [18].
Hence, it can be summarized that the structural layers within the valve are
arranged such that they are anisotropically oriented, resulting in greater compliance of the
valve in the radial direction as opposed to the circumferential (Figure 2.5) [17]. As such,
the valve has unequal mechanical properties in different directions. This allows the cusp
thickness to vary from 300-700 µm throughout the course of the entire cardiac cycle [19],
and thus decreases the chance of impeded blood flow. Furthermore, the different
structural components and their specific functions within each of the layers of the cusps
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work to transfer stresses that allow for coaptation of the valve. As visualized in the stressstrain curve in the Figure 2.5, during opening, elastin extends at minimal load during the
extension of the collagen crimp and corrugations. The collagen in the fibrous layer is
arranged and fold in a lengthwise manner, and is oriented towards the commisures such
that this reduces sagging in the cusp centers and conserves maximal coaptation, thereby
preventing regurgitation [17]. Then, near full closure of the cusp, and thus complete
collagen unfolding (diastole), the load-bearing element shifts from elastin to collagen
[17]. Stress rises progressively while coaptation is maintained. Returning to systole, the
elastin restores the contracted configuration of the cusp and the cycle can begin again.
Thus, both the macroscopic valve geometry of collagen and elastin and the fibrous
components within the valve work to transfer stresses caused by the diastolic force to the
aortic wall and the annulus, minimizing the stresses the cusp itself must continuously
experience [20]. This is an important concept to consider for tissue engineering of
heart valves.
In studies on normal and pathological valves, it has been observed that the main
determinant of valve stability and durability is the valvular extracellular matrix (ECM),
comprised of the collagen, GAGs, and elastin [21]. Most of the mechanical strength of
the valve is provided by collagen, which is comprised primarily of type I, III, and V
collagen [22]. The quantities of each of these components is conversely determined by
the valvular interstitial cells (VICs) [10, 23] (Figure 4, (B)). As touched upon earlier,
heart valve leaflets experience states of mechanical stress during every cardiac cycle,
such as
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Figure 2.5: (A) Cuspal configuration during and ultra-structural arrangement of collagen
and elastin during systole and diastole for an aortic heart valve and the complementary
biomechanical effects of each of these ultra-structural components elucidated in the
stress-strain plot (B) [20]
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shear stress due to blood blow and when the valve opens, flexure during opening and
closing, and tension when the valve closes [10]. The forces act on the valve at a
microscopic level, translating the forces into biomechanical responses, which are then
transduced into biochemical responses by VICs that, at a cellular level, induce up or
down regulation of ECM synthesis [24].
Another important cell type present in the aortic valve is the valvular endothelial
cell (VEC). It covers the surface of the valve, maintaining a nonthrombogenic bloodtissue interface [25]. The next section will provide more information on the valvular
cells.

2.1.3

Cells of the Native Aortic Heart Valve
There are two main types of cells present in the heart valve: a layer of cells that

cover the valve leaflets known as VECs and the inner cells, VICs. Among the VICs,
some researchers have identified three cellular phenotypes: smooth muscle cells,
arranged in bundles or just as single cells [26, 27], ﬁbroblasts maintaining the
extracellular matrix, and cells that have phenotypic features of both ﬁbroblasts and
smooth muscle cells, referred to as myoﬁbroblasts [28-30]. The unique characteristics of
the myoﬁbroblasts, expressing both skeletal and cardiac contractile proteins, may be
central to the lifelong durability of the valve [29]. In adult valve leaﬂets, the more
quiescent ﬁbroblast phenotype predominates among the VICs, characterized by the
expression of vimentin and low expression of α-smooth muscle actin (α-SMA) [24].
During development and adaptation due to diseases, the phenotype of the cells is shifted
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towards a more activated myoﬁbroblast phenotype, characterized by vimentin and αSMA coexpression and secretion of proteolytic enzymes that are capable of degrading the
matrix, mediating matrix remodeling [31]. This is important when considering tissue
engineering applications because these can be helpful markers to assess (vimentin and αSMA) as indicators of an engineered tissue’s potential to remodel. Various types of these
proteolytic enzymes (MMPs) and their tissue inhibitors (TIMPs) are present in normal
valve leaﬂets in a speciﬁc proﬁle and on speciﬁc locations [32] (see section Valvular
Repair and Remodeling for further details).
Professor Avrum I. Gotlieb recently proposed to categorize five phenotypes that
represent VICs: embryonic progenitor endothelial/mesenchymal cells, quiescent VICs
(qVICs), activated VICs (aVICs), progenitor VICs (pVICs), and osteoblastic VICs
(obVICs), as shown in Table 2.1 [33]. Based on this data, VICs seem to express a variety
of defined phenotypes associated with remodeling and repair, in balance within a
functioning valve; changes in this balance can lead to valve pathology.
When the cells change their phenotype (such as during development and
adaptation to higher loads), this balance will be shifted towards one enabling matrix
remodeling. The distribution of the various phenotypes among the valvular interstitial
cells in the aortic valve leaﬂet depend on the biological and mechanical
microenvironment [24]. In the normal adult aortic valve leaﬂet, ﬁbroblasts are mainly
found in the ventricularis, while myoﬁbroblasts and smooth muscle cells are usually
segregated in the ﬁbrosa [34]. A comparable distribution pattern can be found in the
vascular wall with myoﬁbroblasts and smooth muscle cells in the medial layer and
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ﬁbroblasts in the adventitial layer. In the case of hypertension, ﬁbroblasts of the
adventitia convert into myoﬁbroblasts to adapt to the higher mechanical loads [35].

Classification of VIC Markers and Functions into Five Phenotypes
Cell type

Location

Function

Embryonic progenitor
endothelial/mesenchymal
cells

Embryonic
cardiac
cushions

Give rise to resident qVICs, possibly
through an activated stage. EMT can be
detected by the loss of endothelial and the
gain of mesenchymal markers

qVICs

Heart valve
leaflet

Maintain physiologic valve structure and
function and inhibit angiogenesis in the
leaflets

pVICs

Bone marrow,
circulation,
and/or heart
valve leaflet

Enter valve or are resident in valve to
provide aVICs to repair the heart valve,
may be CD34-, CD133-, and/or S100positive

aVICs

Heart valve
leaflet

α-SMA-containing VICs with activated
cellular repair processes including
proliferation, migration, and matrix
remodeling. Respond to valve injury
attributable to pathological conditions and
abnormal hemodynamic/ mechanical
forces

obVICs

Heart valve
leaflet

Calcification, chondrogenesis, and
osteogenesis in the heart valve. Secrete
alkaline phosphatase, osteocalcin,
osteopontin, bone sialoprotein

Table 2.1: VIC markers and Classification into Five Phenotypes [37]

This same adaptation process might explain the distribution pattern of cellular
phenotypes in the aortic valve leaﬂets. But due to the pressure difference over the
leaﬂets, more smooth muscle-like cells are expected in the ﬁbrosa compared to the
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ventricularis [24]. Pressure levels may inﬂuence differences between pulmonary valve
leaﬂets and aortic valve leaﬂets as well [34] .
The idea that cells within the valve play major roles in overall valve dynamics
was further substantiated when a smooth muscle cell system in the leaflets was identified
[26]. The smooth muscle cells are terminally differentiated and arranged in small bundles
in the ventricularis, running circumferentially, or as individual cells [27]. Also,
contractile properties of these VICs were observed [28, 36, 37], as well as sensory nerve
elements in the leaﬂets [38]. Therefore, active contraction of the smooth muscle cells
within the leaﬂets might help to sustain the hemodynamic forces that are exerted on the
leaﬂets during systole and diastole, either by assisting the valve in opening or to provide
support during diastole [27, 37], and represents a reactive cytoskeleton that can anchor
collagen ﬁbrils during valve closure [28].
The endothelial cells covering the surfaces of the leaﬂets provide a protective,
non-thrombogenic layer. It is noteworthy that the endothelial cells on the leaﬂets are
aligned perpendicular to the direction of the ﬂow, as opposed to the alignment of
endothelial cells in the direction of the ﬂow in blood vessels. This indicates that a
mechanical force, other than ﬂow, induces this endothelial cell alignment on the leaﬂets.
As the alignment is similar to the alignment of the collagen ﬁbers, it has been
hypothesized that the pressure stresses during diastole, responsible for the alignment of
the collagen ﬁbers, are responsible for the alignment of the leaﬂet endothelial cells. The
only spot where the endothelial cells align in the direction of the ﬂow is at the nodulus
[39].
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Therefore, it can be concluded that both the VIC and VEC cells within an aortic
heart valve perform active and dynamic functions that contribute to the overall structural
integrity and functionality of the heart valve. Thus, when considering tissue
engineering applications, these cell types and their distribution must be considered.

2.2

Heart Valve Disorders
Valvular heart disease, or valvulopathy, is the generic name given to any

dysfunction or abnormality of one or more of the heart’s four valves. According to the
American Heart Association’s 2006 Heart and Stroke Statistical Update, valvular heart
disease is responsible for nearly 20,000 deaths each year in the United States and is a
contributing factor in about 42,000 deaths. The majority of these cases involve disorders
of the aortic valve (63 percent) and the mitral valve (14 percent) [40], making the
research of treatments for aortic valve disorders an important field. When considering
tricuspid valve disease, it affects about 0.8% of the general population in the United
States [41], most commonly secondary to left-side valve disease, particularly mitral valve
disease [42].
Most experts assert that patients with chronic aortic valve disease can be divided
into three primary groups: inflammatory, which includes septic and rheumatic lesions,
congenital, and degenerative [43].

Ultimately, however, the resulting pathology is

stenosis, insufficiency (regurgitation), or a combination of both [44]. Stenosis is defined
as the failure of a valve to open completely, thereby impeding forward flow and is most
commonly a result of a cuspal abnormality [45-47]. Insufficiency, regurgitation, or
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incompetence, in contrast, results from failure of a valve to close completely, thereby
allowing reversed flow, and is most often a result of failure of the valves supporting
structures, such as the ventricular wall or the chordae tendinae [45-47]. Dysfunction may
vary in degree from slight and physiologically unimportant to severe and rapidly fatal,
with the 1-year survival rate in patients with severe tricuspid regurgitation is
approximately 60% [48, 49]. Therefore, intervention is in most cases required.

2.2.1

Congenital and Acquired Abnormalities
Even though many patients are asymptomatic, roughly 300,000 patients

worldwide have some type of surgical intervention to treat malfunctioning valve annually
[42]. However, in children and infants, the prospect of surgical intervention and potential
valve replacement poses both technically complex and complicated long-term
management issues that differ from those of adults [50].
Of the possible aortic valve dysfunctions, bicuspid aortic valve disease is the most
common type of aortic valve abnormality [51]. Bicuspid aortic valve disease is a
congenital condition and occurs in about two percent of the population [52]. Instead of
the normal three leaflets or cusps, the bicuspid aortic valve has only two. Without the
third leaflet, the valve may be well-functioning, as for about two-thirds of people who
have this defect have a bicuspid valve that functions well for life, stenotic, which causes
the valves to be stiff and therefore leads to the improper opening and closing described
above, or leaky (regurgitation), because it is not able to close tightly [52]. Patients with
congenital or bicuspid aortic valve disease often do not require aortic valve surgery until
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they are adults, however younger patients usually do experience a leaky valve [52]. The
leaky valve can lead to insufficiency and peripheral circulatory problems, therefore it is a
condition that cannot be ignored.

Figure 2.6: (A) Normal, tricuspid aortic valve. (B) Congenital, bicuspid aortic valve [51]

As stated previously, valvular heart disease, particularly in infants and children, is
either congenital or acquired. Congenital abnormalities, including structural defects, such
as the bicuspid valve described above, whether it be a fused, absent, or extra valve leaflet,
and annulus hyperplasia, can be due to abnormal embryonic development. In all,
cardiovascular malformations are the most common congenital abnormality, affecting 4
to 6 in 1000 births, with valve defects accounting for up to 30% of these deficiencies [53,
54]. On the other hand, acquired valvular disease, referring to pathologic changes caused
by inflammatory or degenerative processes, could result from diseases such as infective
endocarditis or acute rheumatic fever [50]. These, however, are less common than the
congenital bicuspid valve described above.
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2.2.2

Age-related Abnormalities
In addition to the congenital and acquired dysfunctions, there are age-related

issues associated with valvular disease witch increases in prevalence with advancing age,
afflicting 4% of the population by age 80 years [55]. In particular, one must consider
calcific aortic stenosis. The natural progression of this condition has shown that severe
symptomatic aortic stenosis is associated with a life expectancy of less than 5 years [56].
But despite the high prevalence of this condition, little is known regarding the molecular
basis of calcific aortic stenosis (Figure 2.7).

Figure 2.7: (A) shows an aortic valve with senile calcific aortic stenosis [57] and (B) a
severely calcified aortic valve [58]

Studies have determined that mature lamellar bone formation occurs in calcified human
aortic valves and that these valves express osteopontin, a bone matrix protein important
in the development of cardiovascular calcification [59, 60]. Furthermore, it has have also
been shown that human aortic valve cell cultures in vitro contain a calcifying cell
population possessing osteoblast-like features [59]. While some have studied this
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condition, it is still a significant problem for both aging and bioprosthetic heart valves, as
will be discussed below.

2.2.3 Valvular Repair and Remodeling
In response to valvular injury or insult, interstitial cell proliferation and migration
occurs-the first events of valve repair [61, 62]. The migration is likely directed by the
activation of integrins and other cell-surface receptors that control cell-ECM adhesion
[52]. Signaling mechanisms further determine how cytoskeletal proteins react by guiding
cell spreading, contraction, and translocation, as would be typical in wound healing [19,
63, 64]. The VICs also play a large part in repair. It has been suggested that the interstitial
cells may activate from a quiescent state (as described before) to help establish and guide
a biomechanical response when the valve is exposed to a new mechanical environment,
as would be expected during injury [19, 23]. This is accomplished by a phenotypic
change in the VICs, which is determined by the wall stresses in the leaflets [65]. (Please
recall Aortic Valve Cell section for phenotypic changes, page 17)
It is also thought that the interactions between the VICs and the matrix play a
large part in regulating interstitial cell-based remodeling, including the induction of cell
migration, the secretion of ECM components, and the secretion of proteolytic
components- all key parts of the tissue repair process [66]. This is evident by the fact that
collagenases, gelatinases, and other matrix metalloproteinases (MMPs) have been
isolated from heart valves [32]. Actually, it is thought that MMPs and tissue inhibitor of
metalloproteinases (TIMPs) play a key role in tissue remodeling and regeneration [67,
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68], with their interactions and the interactions between both the MMPs, TIMPs, and
their receptors of particular importance in cardiac remodeling [19]. For example, MMP-1
and MMP-13 have been shown to mediate the initial phase of collagen degradation by
disassembling the fibrillar collagen native helix, thus contributing to remodeling [66].
The fibrillar fragments are then susceptible to other proteases, such as gelatinases, or
elastases like cathepsin K [69]. And since the level and pattern of MMP and TIMP
expression in normal valves is very specific [32], excess levels of these proteolytic
enzymes may cause collagen and elastin degradation and result in weakening or
destruction of the heart valve. Notably, some valvular pathologies have been associated
with an over expression of MMPs by the valve’s own cells, leading to ECM degradation
[65] (Figure 2.8).

Figure 2.8: Pathologic valves may have an abnormal layered architecture: loose collagen
in ﬁbrosa, expanded spongiosa strongly positive for proteoglycans, and disrupted elastin
in ventricularis [adapted from 65]
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These findings may suggest that cells are being stimulated to produce and secrete
second messengers that prompt native cells to degrade the matrix [70]. Therefore, since
MMPs are important for remodeling of tissue engineered scaffolds, their activity must be
tightly regulated and controlled in these situations to prevent deleterious events and valve
failure.

2.3

Treatments of Valvular Pathology
Even though there are is no medicinal treatment for valvular disease, a physician

will most likely recommend medications to control blood pressure and will place
limitations on strenuous activity (especially lifting heavy objects), particularly for those
with aortic stenosis. However, if symptoms are present or there is severe ventricular
dysfunction with either stenosis or regurgitation, further surgical intervention will be
warranted [71].

2.3.1 Minimally Invasive Treatments
In some heart conditions minimally invasive surgical approaches via catheters can
provide results comparable to those one would expect to experience with surgery. While
most patients are able to undergo surgery without difficulty, for people whose heart
function is too severely compromised to withstand surgery, several approaches to treat
heart valve disease without surgery have been developed. One example is percutaneous
valvotomy, or valvuloplasty (Figure 2.9) [1].
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Figure 2.9: Mitral valvotomy [1]. Please see details in text below

Valvotomy can be performed in some patients to treat aortic valve stenosis or
mitral valve stenosis [72, 73]. During an aortic valvotomy, a catheter is placed through
the femoral vein (in the groin) and guided into the chambers of the heart. The cardiologist
then creates a tiny hole in the wall between the heart’s two upper chambers, providing an
opening for access to the left atrium with a special catheter that has a balloon at the tip.
The catheter is positioned so the balloon tip is directly inside the narrowed aortic valve
(Figure 2.9(A)) while the valve opening is dilated by rapidly inflating and deflating the
balloon (Figure 2.9(B-D)) [1].
Other investigational options are being explored as alternatives to invasive
surgical procedures, the first of which is a possible percutaneous aortic valve replacement
(AVR). Percutaneous AVR is a new treatment being investigated for select patients with
severe symptomatic aortic stenosis [72]. It is also being investigated as a possible
technique for implanting a prosthetic valve inside the diseased calcific aortic valve. The
procedure is performed in the catheterization lab [1, 72]. During the procedure a catheter
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is placed through the femoral artery and guided into the chambers of the heart. A stentmounted, compressed tissue heart valve is placed on the balloon-mounted catheter and is
positioned directly over the diseased aortic valve. Once in position, the balloon is inflated
to secure the valve in place (Figure 2.10) [1]. This holds great possibilities as a
deployment method for tissue engineered heart valves. As such, the implantation
method must be considered in the design process of the valve.

Figure 2.10: Percutaneous aortic valve replacement (AVR) [1]. A balloon catheter is
placed in the diseased aortic valve orifice (A,B) and is inflated to deploy the tissue valve
(C,D)

2.3.2 Surgical Repair Treatments
There are several options for young adult patients with aortic valve disease. The
type of aortic valve surgery that is recommended is based on several factors, including
the age of the patient, the expected long-term survival, any co-existing medical
conditions including the type of valve disease, other types of heart disease, or other
medical conditions, certain surgical risks, including the risk of thromboembolism, the risk
of endocarditis, and the overall durability of the valve [74]. Along with the type of valve
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chosen comes the risk of bleeding complications with long-term anticoagulation therapy.
Most adolescent and young adult patients are concerned about aortic valve surgery
because they want to maintain an active, normal lifestyle, including sports, travel,
pregnancy, etc., and they wish to avoid the use of anticoagulant medications, which some
patients are required to take after valve surgery (as for mechanical valves, which will be
discussed). They also hope to avoid the need for future surgeries, which are in many
cases necessary. Fortunately, in addition to complete valve replacements, there are other
options for the treatment of valvular pathologies. One of these options is aortic valve
repair [75]. Aortic valve repair may be an option for patients who have bicuspid aortic
valve disease or other aortic valve conditions that are associated with valve regurgitation
[75].
Even though aortic valve repair is not performed very often because it is
technically very difficult, the majority (two-thirds), of leaky bicuspid aortic valves can be
repaired with good results [51]. This type of surgery may be advantageous because the
natural anatomy of the heart, as well as heart muscle strength, is preserved. There is also
a decreased risk of infection, as opposed to complete valve replacement, and need for
life-long anticoagulant medication [51, 76-78].

Figure 2.11: Aortic valve repair of a congenital bicuspid aortic valve, depicting
shortening of the abnormal cusp [51].
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However, there are drawbacks to this type of surgery. For one, this type of aortic
valve surgery is technically difficult and is really only an option for leaky aortic valves,
not stenotic valves [75]. Although a repaired valve can possibly last a lifetime, about 20
to 25 percent of patients will require a valve replacement within ten years [51, 76]. In the
best case scenario, the repaired aortic valve will function like a well-functioning bicuspid
valve.

Figure 2.12: The Ross Procedure- In (1), the measurements of the aortic and pulmonic
valves are taken, then (2) the aorta and pulmonary artery are opened and the aortic and
pulmonary valves are inspected to determine if the Ross is an appropriate procedure.
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Next (3), the diseased aortic valve is removed and the pulmonary valve (autograft) is
removed and placed in the aortic position. The autograft is sutured in place (4) and the
coronary arteries are re-attached. A pulmonary homograft is then attached to the right
ventricle outflow tract (5). Finally, the aorta is attached to the autograft and the
pulmonary artery is attached to the homograft (6) - the procedure is complete [51].

Another alternative to valve replacement is a procedure known as the Ross
operation (Figure 2.12 above), or the Switch procedure as it is commonly referred [79].
The Ross procedure is usually performed on patients younger than ages 40 to 50 who
want to avoid taking long-term anticoagulant medications after surgery [79]. During this
procedure, the patient's own pulmonary valve is removed and used to replace the diseased
aortic valve. The pulmonary valve is then replaced with a pulmonary homograft [51, 79].
This procedure may be an attractive alternative to replacement with mechanical or
xenogenic tissue valves in the aortic position because the pulmonary valve is
anatomically very similar to the aortic valve and could be an ideal substitute for the aortic
valve. Also, as opposed to mechanical valves, the new aortic autograft is a living valve
and it may grow as the young adult grows, making this a good option for young patients.
And given that the blood flows with less pressure through the pulmonary valve than the
aortic valve, a homograft valve could last longer in the right-sided pulmonary valve
position rather than the aortic position. Furthermore, the risk of thromboembolic
complications and the risk of valve infection are very low. Moreover, the hemodynamic
performance makes the Ross operation an attractive alternative for athletes [10, 51].
Ultimately, the pulmonary autograft valve has a good chance of being a life-lasting
solution for the aortic valve (it is speculated that the pulmonary autograft will last a
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lifetime in at least half the patients that undergo the Ross procedure [79]), making it an
attractive alternative to conventional valve replacements.
However, there are drawbacks to this procedure that make it not the most
attractive option for some patients. The Ross procedure is a technically difficult and long
surgery, as it requires two valve replacements. As a consequence, this procedure is only
recommended for young patients who would tolerate a long surgery time [80]. Also, the
pulmonary autograft valve is transplanted from the low pressure pulmonary circulation
over to the aortic high pressure system [51]. While the valve cusps are strong enough to
withstand the systemic pressure, the pulmonary artery wall does dilate when exposed to
systemic pressure, occasionally enough to cause the autograft valve to leak. Therefore,
the risk of requiring re-operation for a leaking autograft valve is about 10 percent within
10 years after the operation [79]. Also, the Ross procedure is not recommended for
patients with tissue defects (such as Marfan syndrome) or for patients who have an
abnormal pulmonary valve [80]. The pulmonary homograft in the pulmonary position
could also fail; the most common reason for failure is that it becomes stenotic. The risk of
requiring replacement of the pulmonary homograft is about 10 percent within 10 years
after the procedure[79]. Therefore, while there are surgical options for repairing a
compromised aortic valve, the risk associated with the surgery and the prospect of
resurgeries in some instances may be worse than the disorder.
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2.3.3 Heart Valve Replacements and Devices
As stated previously, valvular heart disease represents a significant cause of
mortality worldwide. Diseases can affect any of the four heart valves, although diseases
of the aortic valve occur most frequently, associated with high mortality rates. And when
the non- surgical and minimally invasive approaches fail to ameliorate the symptoms
caused by a dysfunctional heart valve, the most common treatment for end-stage valvular
diseases is surgical replacement of the valve. Historically there have been two types of
artificial heart valves that are implanted- mechanical and tissue-based [81, 82]. Today,
while mechanical valves contribute to approximately 60% of replacements, tissue valves
are used in 40% or more of valve replacements world-wide, whether as autografts or
allografts, or more predominantly as stented porcine aortic valve and bovine pericardial
valves preserved by glutaraldehyde (collectively termed bioprostheses) [20]. None of
these devices, however, is without complications.

Figure 2.13: Images of contemporary valves implanted into patients today. (a) Bileaﬂet
mechanical
valve, (b) single leaﬂet mechanical valve, (c) bovine pericardial
bioprosthesis, (d) stented porcine xenograft valve, (e) stentless porcine xenograft, and (f)
the human aortic valve homograft[83].
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2.3.3.1 Clinical Practice
The ideal, or ultimate, replacement heart valve would have to function
immediately after implantation, would have increased durability than the replaced valve,
would be conductive to repopulation with host cells, and would have remodeling
potential, or the ability to grow with the patient. Of the currently available replacements,
no one valve fulfills all the above requirements. However, each has advantages and
disadvantages over the others.

2.3.3.2 Autografts and Allografts
Cryopreserved aortic donor valves are the heart valve replacements closest to the
natural valve, not being thrombogenic and with a low risk of infection. They are not
chemically cross-linked and exhibit good mechanical properties, which prolongs their
lifetime [84]. However, their disadvantages are their limited availability, a more difficult
implantation technique [85] and failure associated with a speciﬁc immune response,
especially in young children [86]. The use of cryopreserved pulmonary homografts as
aortic heart valve replacements has been shown to result in early failure as the ﬁber
structure of the pulmonary valve is less resistant to the hemodynamic environment in the
aortic position compared to cryopreserved aortic valves [87]. Furthermore, these valves
were shown to suffer from gross regurgitation in vitro, only augmenting the underlying
cause for a replacement [88].
A controversial issue regarding cryopreserved homografts concerns the viability
of the native endothelial and interstitial cells. A lack of viable cells after implantation was
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stated [20] as well as the long-term survival of cellular elements [89]. In general,
although cryopreservation reduces cellularity, the expression of strong antigens could still
be demonstrated, and this might trigger the immune system of the host, resulting in graft
rejection [90].

Figure 2.14: Allograft Valve Replacement- An allograft is an aortic or pulmonic valve
that has been removed from a donated human heart, preserved, antibiotic-treated, and
frozen under sterile conditions. A homograft may be used to replace a diseased aortic
valve, or it may be used to replace the pulmonic valve during the Ross procedure [51].

2.3.3.3 Mechanical Heart Valves
Mechanical heart valve replacements display good structural durability, but are
associated with a risk of prosthetic valve endocarditis and high rates of thromboembolic
complications caused by their non-physiological surface and ﬂow abnormalities[80].
Life-long anticoagulation therapy is necessary in these patients, which is associated with
a substantial risk of spontaneous bleeding or embolism, particularly in patients aged over
70 years [91, 92]. Mechanical valves are of rigid construction and because of ﬂow
patterns and material properties, induce blood clotting on their surface. In the 1960s and
1970s, some of these valves failed catastrophically by having a leaﬂet dislodge and
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flow into circulation (causing embolic complications) or a portion of the cage break,
which could be fatal [83, 93, 94] (Figure 2.15 below for examples of mechanical valves)

Figure 2.15: (A) and (B) are examples of a ball and cage and disk mechanical valve,
respectively, which are no longer used, while (C) shows a conventional mechanical heart
valve in use today [adapted from 95].

Currently, the most serious drawback to the use of mechanical valves is the
anticoagulation therapy. Chronic anticoagulation is associated with cumulative morbidity
and mortality, often as high as 4% per year [96, 97], which essentially guarantees some
serious event within a 25-year implantation period [80]. This is particularly distressing
for pediatric applications, where there is not only the prospect of multiple surgeries to
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correct valve malfunctions, but the ever changing myocardium of a young mechanical
heart valve recipient would necessitate further surgeries to accommodate the growing
heart

2.3.3.4 Bioprosthetic Heart Valves
Bioprosthetic heart valve (BHV) replacements are of animal origin (xenografts),
such as porcine aortic valves and bovine pericardial valves. Xenografts are chemically
cross-linked - this inhibits autolysis, enhances the mechanical stability, and creates the
possibility of having valves of different size directly available. However, these valves
differ in many respects from native valves, for example in their opening and closing
behavior due to the chemical pre-treatment [20]. Explanted xenografts were shown to be
stiffer in the radial direction and less stiff in the circumferential direction compared to
native porcine valves [98]. The risk of thromboembolic complications is much lower, but
the valve’s durability is limited. Structural failure is strongly age-dependent, making
xenografts attractive for the elderly, but less suitable for children and young adults [20].
One important aspect in xenotransplantation is the risk of zoonoses - human
diseases caused by infectious agents from animals [99]- which might even be facilitated
by the mandatory immunosuppression [100, 101], but this is not necessary for BHVs. The
identiﬁcation of porcine endogenous retroviruses and prionic diseases has given rise to
great concern. Recently, epidemiological data have strongly indicated transfer of
Creutzfeldt-Jakob disease from cattle into humans either via infected meat, via surgical
materials derived from bovine gut, or via drugs or vaccines prepared using fetal calf
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serum [102]. Porcine endogenous retroviruses (PERV) can be present in all organs, as
multiple copies of PERV can be integrated into germ-line DNA. New and more
infectious groups of PERV are being identiﬁed [103], as well as their capacity to infect
various types of human cells in vitro [104, 105]. One antigen that has been implicated in
xenogenic transplantation rejection is galactose-alpha(1–3)-galactose (αGal), which are
carbohydrate residues present on cell-surface glycoproteins and glycolipids of porcine
tissue, but not human tissue [106].
Xenografts are attractive alternatives to homografts as a replacement for an
injured valve because sufficient numbers can be obtained [107, 108]. Using the bovine
pericardium or porcine heart valves in the manufacture of these valves has become
somewhat standard, but these two tissues differ significantly in both structure and overall
function. The bovine pericardium is more structurally homogeneous than the porcine
tissue with respect to collagen and elastic fiber orientation, while the porcine tissue is less
uniform. However, the porcine valve leaflet does contain a spongiosa layer, like the
human leaflet and unlike the bovine pericardium. This spongiosa accumulates large
deposits of proteoglycans that serve to reduce friction between the other two layers, again
as in the human valve, but upon processing, are usually lost, leaving empty spaces for
which may serve as sites for hydroxyapatite crystal nucleation, leading to calcification
[109-112]
But, as stated for any tissue implant, the immediate problem with these devices is
the preservation and sterilization of the tissue. Initial fixatives included the use of
mercury salts and formaldehyde and finally glutaraldehyde (Glut) [109]. Glutaraldehyde
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is a five-carbon dialdehyde that reacts directly with primary amines on residues of the
amino acids lysine and hydroxylysine (found in abundance in the collagen of pericardial
tissue and valves) [113-116]. Since 1970, glutaraldehyde has become the general fixative
treatment, but there remain a number of problems with these treatments. Although Glut
bioprostheses mimic natural aortic valve structure, their cells are nonviable and thereby
incapable of normal turnover or remodeling ECM proteins [20], Glut-fixed tissue is much
stiffer than natural cup tissue, which can lead to greater internal stresses in bending [117],
and their mechanical properties are markedly different from those of natural aortic valve
cusps. Consequently, tissue valves suffer a high rate of progressive and age-dependent
structural valve deterioration resulting in stenosis or regurgitation [20].
Two distinct processes- intrinsic calcification and noncalcific degradation of
the ECM account for structural valve deterioration. Calcification is a direct consequence
of the inability of the nonviable cells of the Glut-preserved tissue to maintain normally
low intracellular calcium. Calcification begins in the cells as crystalline deposits, then
nucleation of calcium-phosphate crystals occurs in the collagen and elastin [20, 118].
Noncalcific degradation in the absence of physiological repair mechanisms of the
valvular structural matrix are largely thought to be due to changes to the natural valves
when they are fabricated into a tissue valve and the subsequent interactions with the
physiologic environment that are induced following implantation[20]. However, the
advantages include the fact that Glut is efficient as a sterilizing agent against bacteria,
fungi, and viruses, but one cannot overlook the major problems, that are the propensity of
Glut-treated tissue to calcify and clear cytotoxic effects that render cells not viable [119].
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As a result, numerous experimental chemical treatments, none of which are in
clinical use, are being addressed to alleviate the shortcomings of Glut. Of these, many
attempt to stabilize tissue without the use of aldehydes, such as diphenylphosphoryl
azide, carbodiimide, and hexamethylene diisocyanate [119-121]. Other treatments have
aimed at impeding the harmful effects of glutaraldehye with subsequent treatments with
amino acids that block the aldehyde groups [122-127] or pretreatment with chemicals
(such as neomycin) that specifically target GAGS, that are not at all stabilized with Glut
[128] and subsequently lost in preparations. Another treatment that was used to prepare
tissue, in concurrence with Glut, was pressure fixation. Generally, prostheses made of
porcine tissue are treated with pressures equivalent to diastolic pressure, but these
fixation pressures can affect collagen buckling, loss of endothelium, different degrees of
connective tissue cell autolysis, and the tissue can be rigid and inflexible [129].
Therefore, there is a need for a more adequate fixation method that addresses and
alleviates the shortcomings of the fixatives above.

2.4

Heart Valve Tissue Engineering
The ultimate goal of tissue engineering is to construct tissues from their cellular

components which combine and maintain most of the characteristics of the original,
healthy tissue.

For

a functioning heart valve these include durability, adequate

mechanical function, which correlates with haemodynamic performance, and a mature
extracellular matrix which does not elicit an immunogenic or inflammatory reaction. To
this end, the success of tissue engineered heart valves (TEHV) is dependent on three
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main issues: (1) the scaffold, which determines the three-dimensional shape and
serves as an initial guiding structure for cell attachment and tissue development; (2) the
cell source from which a living tissue is grown; and (3) the in vitro culture
conditions of the living construct before implantation [20].
In order to overcome the limitations of today’s heart valve replacements,
researchers have developed different tissue engineering concepts using various scaffold
materials. These include biodegradable synthetic scaffolds seeded with autologous cells,
decellularized allo- or xenografts seeded with autologous cells (auto-xenograft) or
decellularized allo- or xenografts without cell seeding (Table 2) [130].

Table 2.2: Scaffolds and their potential use in tissue engineering [130]
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Several attempts have been made to create functional heart valve replacements with the
ability to grow, repair, and remodel using the concept of tissue engineering. As
demonstrated by the schematic representations below (Figure 16, A,B), in one approach
to tissue engineering, the patient’s own cells, isolated, for example, from a blood vessel
and expanded using standard cell culture techniques, are seeded on the scaffold, in the
shape of a heart valve.

Figure 2.16 (A): Schematic of principle of tissue engineering of heart valves. 1)
Isolation of cells from a blood vessel of the patient and separation of myoﬁbroblasts and
endothelial cells. 2) Seeding of myoﬁbroblasts onto a scaffold material in the shape of a
trileaﬂet heart valve and subsequent seeding of endothelial cells onto the surfaces. 3) The
cell/scaffold construct is placed into a bioreactor to stimulate tissue development [130].

Subsequent stimulation, transmitted via the culture medium (biological stimuli) or via
’conditioning’ of the tissue in a bioreactor (mechanical stimuli), promotes tissue
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development, resulting in a completely autologous, functional, and living heart valve
implant [20]. However, scaffold seeding has proven to be difficult and incomplete
and mechanical properties are not comparable with native tissue, so improvements
must be made.
Another approach, elucidated by Figure 16 (B), is to implant unseeded scaffolds
designed to encourage cell migration and proliferation. In either approach, the end goal is
the same- to promote cell growth on a tissue engineered scaffold whereby the scaffold
will be incorporated into the body as a living tissue.

Figure 2.16 (B): The paradigm of tissue engineering (Pathway A) The conventional
paradigm of tissue engineering comprises a scaffold that is seeded with cells, an in vitro
stage of tissue formation typically conducted in a bioreactor, and an in vivo stage of tissue
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growth and remodeling. The key processes occurring during the in vitro and in vivo
phases are cell proliferation, ECM production and organization, scaffold degradation, and
tissue remodeling. The resulting tissue engineered construct will contain some
combination of seeded and/or new cells. A modiﬁed paradigm (Pathway B) might utilize
an unseeded scaffold that is fabricated with biological “information” designed to attract
and provide a suitable substrate for differentiation of circulating precursor cells in vivo
[10].

Heart valve tissue engineering represents a promising approach towards
autologous, living, and functional heart valve replacements with the ability to grow,
repair, and remodel. Mechanical conditioning of the developing tissue in a bioreactor has
rendered heart valve replacements, which have shown excellent functionality in sheep
when implanted in the pulmonary position [131]. The pulmonary position is, however,
a low-pressure environment and as most heart valve replacements concern the
aortic valve, a high-pressure environment, the tissue properties of the neo-tissue
have to be optimized further to serve as aortic heart valve replacements.

2.4.1 Scaffolds for Heart Valve Tissue Engineering
As stated previously, the heart valve scaffold may be either based on biological or
synthetic materials. Donor heart valves or animal derived valves depleted of cellular
antigens can be used as a scaffold material. Removing the cellular components results in
a material composed of essentially extracellular matrix proteins that can serve as an
intrinsic template for cell attachment [132]. In general, non-ﬁxed, acellularized valve
leaﬂets have shown recellularization by the host, as demonstrated in dogs [133] and sheep
[134]. However, ﬁrst clinical applications of this concept in children resulted in rapid
failure of the heart valves due to immune rejection as a result of incomplete
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decellularization, and was associated with a 75% mortality [135]. In a further approach,
speciﬁc biological matrix constituents can be used as scaffold material, including
collagens and ﬁbrin [136, 137]. These materials have the disadvantage that they are
difficult to obtain from the patient in sufficient quantities. Therefore, most of these
scaffolds are of animal origin. In this context, identiﬁcation of retroviruses and prionic
diseases has given rise to great concern as to the risk of zoonoses.
An ideal synthetic scaffold for tissue engineering applications must be at least
90% porous [138], and must possess an interconnected pore network, as this is essential
for cell growth, nutrient supply, and removal of metabolic waste products. Besides being
biocompatible, biodegradable, and reproducible, the scaffold should also display a cellfavorable surface chemistry and, as stated above, match the mechanical properties of the
native tissue [20]. The rate of degradation should be proportional to the rate of tissue
formation and controllable in order to ensure mechanical stability over time [139, 140].
The use of synthetic materials as scaffolds has already been broadly demonstrated for
heart valve tissue engineering. Initial attempts to create single heart valve leaﬂets were
based on synthetic scaffolds, such as polyglactin, PGA (polyglycolic acid), PLA
(polylactic acid) and PLGA (copolymer of PGA and PLA). To create complete trileaﬂet
heart valve conduits, PHA based materials (polyhydroxyalkanoates) were used [141]. A
combined polymer scaffold consisting of non-woven PGA and P4HB (poly-4hydroxybutyrate) has shown promising results in sheep, when placed in the pulmonary
position [131]. These materials are thermoplastic and can therefore be easily molded into
any desired three dimensional shape [130]. These above materials are approved for
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surgical use and they are biocompatible and biodegradable. A major advantage

of

synthetic matrices is the fact that their biodegradation properties and biomechanics
can

be chemically designed

according

to

the

requirements of the

particular

application. Moreover, specific proteins such as growth factors may be incorporated
into the scaffold structure enabling targeted promotion of specific tissue growth [130,
142] . However, success of synthetic leaﬂet HVs has also been hampered by their
impaired haemodynamic performance compared with the performance of natural valves
[143] and the fact that they have their limited durability are susceptible to calciﬁcation,
which leads to leaﬂet stiffening and tearing [144].

2.4.2 Alternative Cross-linking Methods
As discussed with bioprostheic valves, tissue engineered valve replacements
based on biological scaffolds are subject to degradation and stability concerns. And like
bioprosthetic replacements a possible way to increase the resistance of natural tissueengineered scaffolds to proteolytic degradation is to use chemical stabilizing and/or
cross-linking agents. Several

cross-linking

and

stabilizing

agents (such as

glutaraldehyde and proanthocyanidin) and methods have been proposed and tested with
different degrees of success [152, 153] however the ideal or at least clinically optimal
stabilizing agent has not yet been identiﬁed.
Recently tannic acid (TA) and tannic acid mimicking dendrimers (TAMD) have
been suggested as potential cross-linking agents for collagen [154-156]. It was also
shown that addition of TA to glutaraldehyde (Glut) pretreatment dramatically
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improves elastin and collagen stabilization in cardiovascular implants as evidenced by an
increased resistance to

proteolytic

degradation [157]. Moreover, TA has 10 times

lower toxicity as compared to Glut [157].
One tannin in particular that is being investigated is penta-galloyl glucose (PGG).
It is a naturally derived polyphenol present in plants and is currently available in pure
form from several manufacturers. Structurally, it belongs to the galloyl-glucose family
(syn. gallotannins), characterized by a D-glucose molecule esterified at all five hydroxyl
moieties by gallic acid (3,4,5 -trihydroxybenzoic acid) (Figure 17).

Figure 2.17: Structure of PGG. Five gallic acid residues (pink dotted lines) are bound to
each of the hydroxyl groups of a glucose core (blue). At right, spatial configuration of the
PGG molecule.

This core molecule may be derived by addition of gallic acid, to yield structures that may
contain a total of 10-12 galloyl residues, also known as tannic acids [158] Polyphenols
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have a hydrophobic internal core and numerous external hydroxyl groups. By virtue of
this structure, they react with proteins, specifically binding to hydrophobic regions [159],
but also establishing numerous hydrogen bonds, showing particularly high affinity for
Proline-rich proteins[160] such as collagen and elastin [161]. In addition, they inhibit
many enzymes, are efficient antibacterial agents and reduce inflammation and
antigenicity [158]. Polyphenols have very low toxicity in animals (LD50 = 6 g/kg, orally
in mice, LD50 = 700 mg/kg i.p. in rats, LD50 = 80 mg/kg i.v. in rats, as per Merck
Index). Recently we also showed that peri-arterial delivery of PGG to rat abdominal aorta
prevented aneurysm formation or progression and did not elicit any detectable changes in
serum liver enzyme activities or liver histology, clearly showing that PGG was not toxic
[162]. Moreover, extractables obtained from PGG-fixed tissues exhibited very low in
vitro cytotoxicity towards fibroblasts and smooth muscle cells (less than 10%)[163] and
thus can be used safely in tissue engineering applications.

2.4.2 Cell Sources for Heart Valve Tissue Engineering
As briefly explained above and visualized in Figure 16 (A), in most
cardiovascular tissue engineering approaches cells are harvested from donor tissues.
From peripheral arteries, for example, mixed vascular cell populations consisting of
myoﬁbroblasts and endothelial cells can be obtained. Out of these, pure viable cell lines
can be easily isolated by cell sorters [145] and the subsequent seeding onto the
biodegradable scaffold is undertaken in two steps. First the myoﬁbroblasts are seeded and
grown in vitro and second, the endothelial cells are seeded on top of the generated neo-
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tissue leading to the formation of a native leaﬂet-analogous histological structure [146].
With regard to clinical applications, several vascular human cell sources have been
investigated [147]. Recently, cells derived from bone marrow or umbilical cord have
been successfully utilized to generate heart valves and conduits in vitro [148-150]
(Figure 18).

Figure 2.18: Differentiated human umbilical cord cells showing in (A) Hematoxylineosin and (B) Masson’s trichrome staining cells with a ﬁbroblast morphology and
deposition of extracellular matrix proteins. Immunoﬂuorescence staining demonstrated
expression of (C) vimentin and (D) alpha-smooth muscle actin [148].

In contrast to vascular cells, these cells can be obtained without surgical
interventions representing an easy-to-access cell source in a possible routine clinical
scenario.

Due to their good proliferation and progenitor potential, these cells are
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expected to be an attractive alternative for cardiovascular tissue engineering applications.
Apart from the use of so called progenitor cells, the research on stem cells and their
differentiation pathways is still in its infancy and a drawback is the possible
immunogenicity of these cells. This may be solved by genetic engineering [151],
although this is still in the experimental phase. The best option for stem cell use is to
use autologous stem cells and, using both mechanical and biochemical cues,
differentiate these into VICs.

2.4.4 Conditioning of Tissue Engineered Heart Valves
Tissue formation can be stimulated by either biological or mechanical
conditioning. Biological conditioning involves addition of cytokines either directly to the
growth medium or by incorporation into the scaffold material. Cytokines are a group of
regulatory molecules that function as mediators of cell communication and can exert
multiple biological functions by interaction with speciﬁc cell surface receptors. The
family of cytokines includes interleukins, hematopoietic growth factors, interferons,
tumor necrosis factors, and growth factors [164]. Well-known cytokines that inﬂuence
vascular cell behavior are ﬁbroblast growth factor (FGF), platelet-derived growth factor
(PDGF), transforming growth factor-β (TGF-β), and vascular endothelial growth factor
(VEGF) [165, 166] Besides cytokines, regulating cell behavior, matrix metalloproteinases
(MMPs) play an important role in tissue development and subsequent remodeling [167].
When cytokines are directly applied to the growth medium, the effect is short term and
should be repeated several times. When incorporated into a biodegradable scaffold
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material, slow release can be obtained by coupling of the cytokine release to the
degradation rate.
Mechanical conditioning involves the application of various mechanical stimuli in
a bioreactor, such as ﬂows, inducing shear stresses over the developing tissue, and
strains, being either dynamic or static in nature. For engineering of heart valves, the most
commonly used bioreactor is a pulse duplicator system, in which the normal opening and
closing behavior of the valve is mimicked [168, 169]. In this type of bioreactor, the tissue
is exposed to increasing ﬂow rates and pressures. Recently, new bioreactors have been
developed for tissue engineering of heart valves, in which the exact physiological
conditions of a heart valve in vivo can be applied [170-172]. Mechanical and biological
stimuli do interact in a very complex way in the regulation of tissue behavior. By
mechanical stimuli, the production and secretion of various cytokines by the cells are
increased, or conversely, the addition of cytokines during tissue development can
increase the effect of mechanical conditioning.

2.4.5 Current Tissue Engineered Heart Valve Approaches
Two of the most recent advancements in the field have striven to incorporate the
above concepts of tissue engineering into functional heart valves. The first concept,
published by a group in China, is based on the fabrication of a hybrid heart valve leaflet.
As has been stated before, the formation of tissue-engineered heart valves can be
distinguished by the scaffolding material- bioresorbable polymer scaffold, and
decellularized heart valve scaffold

[173]. It has been shown that the bioresorbable
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polymer scaffold cannot reproduce the functional complex three-dimensional composite
heart valve leaﬂet architecture and has limitations in cellular adhesion. And the use of
a decellularized valve tissue matrix offers the advantages of its innate anatomical
architecture and remaining biomechanical function. Therefore, they have striven to
combine both approaches to form a hybrid biomatrix/polymer heart valve scaffold. The
scaffold was fabricated from decellularized porcine aortic heart valve leaﬂet and coated
with basic ﬁbroblast growth factor (bFGF)/chitosan/poly-4-hydroxybutyrate (P4HB)
using an electrospinning technique. Then, the hybrid heart valve leaﬂet was engineered
by

seeding

mesenchymal stem cells (MSCs) onto the scaffold. Results showed that

MSCs were present on the scaffolds and the electrospun membrane ﬁrmly combined
with the surface of the decellularized valve leaﬂets, concluding that the hybrid leaflets
could be useful for heart valve tissue engineering. However, cellular infiltration into
the scaffold has been limited, resulting in only surface population.
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Figure 2.19: Valve-equivalent (VE) mold and fabrication. Cell-seeded ﬁbrin-forming
solution is injected into the complete mold (left). After gelation, the outer housing and
plug are removed and mold and gel placed in culture medium. Culture for 3 weeks with
gentle rocking results in a compacted bi-leaﬂet VE tissue (right).
The next, and most recently published, by a team lead by Robert Tranquillo, is
based on the entrapment of dermal ﬁbroblasts into ﬁbrin gel within a mold, which,
following static incubation in the mold, yields the gross geometry and alignment patterns
of the native aortic valve [174], as seen in the Figure 18 (above).
The dermal ﬁbroblast is used because it is a readily available source and generates
extensive remodeling of ﬁbrin into a collagenous tissue

with

tensile

mechanical

properties approaching those of native tissue [174]. Dermal ﬁbroblasts have also been
successfully used for a vascular graft in clinical studies [175]. The ﬁbrin-based TEHVs
are cast such that the tubular root and leaﬂets are a single entity. By using molds with two
or three channels cut into the central mandrel, bi- and tri- leaﬂet VEs have been
fabricated.
In contrast to synthetic biodegradable polymers whose initial strength and
stiffness values are greater than heart valve tissue, those of biological scaffolds like
collagen or ﬁbrin are orders of magnitude smaller. And, as stated earlier, realizing tissue
growth to achieve physiological values of leaﬂet tensile and bending stiffness prior to
implantation is crucial for their success. Shown by previous research with ﬁbrin-based
tubular constructs prepared with porcine aortic valve interstitial cells, it was illustrated
that cyclic stretching with an incremental strain amplitude over three weeks can lead to at
minimum an 84% greater ultimate tensile strength compared to statically-incubated
controls, which correlates with increased collagen deposition and maturation [176].
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Therefore, Tranquillo’s team is developing a controlled stretch TEHV bioreactor that can
apply prescribed cyclic stretching to the VE root and leaﬂets during the entire incubation
(even as the tissue mechanical properties change), while independently controlling the
nutrient delivery (see Figure 2.20 below).
It was concluded that using ﬁbrin-based VEs prepared with human dermal
ﬁbroblasts, it is possible to create a TEHV with circumferential ﬁber alignment in the
leaﬂet manifested as anisotropic stiffness comparable to native leaﬂets, a property that
has not been achieved with TEHVs based on synthetic biodegradable polymers. Though
several bioreactors have been proposed to mechanically condition TEHVs, they do not
allow for controlled strain to be applied without complicated feedback regulation,
which has not been proposed. Using a strategy for controlled cyclic stretching of tubular
constructs that they presented previously, they developed a controlled cyclic stretch
bioreactor for TEHVs that leads to improved tensile and compositional properties.
Despite their exciting accomplishments, in vivo studies have been performed in the less
mechanically demanding environment of the pulmonary valve position, where the valve
is exposed to pressures far less than would be expected in the aortic position [177].
Furthermore, from preliminary data presented at the Heart Valve and Tissue Engineering
meeting in Hilton Head (personal communication, March 2010), Dr. Tranquillo presented
data that showed exstensive fibrosis after implantation, suggesting this scaffold may not
be suitable for TEHVs.
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Figure 2.20: (a) Schematic of controlled cyclic stretching TEHV bioreactor showing the
reciprocating syringe pump for cyclic pressurization and stretching of the VE mounted
within the latex tube, (b) image of the bioreactor with the latex housing slit to reveal the
VE mounted within and its tie-down to both end pieces, and (c) end-on view of the VE
through the glass window of the bioreactor during a stretching cycle, showing the leaﬂets
coapting when the lumen is not pressurized, and separated when the lumen is pressurized
and the root and leaﬂets are stretched [177].
Thus, research for an ideal scaffold for heart valve tissue engineering is still needed.
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CHAPTER 3
PROJECT RATIONALE

3.1

Hypothesis
Replacement

or

regeneration

of

heart

valves,

exquisite

examples

of

hemodynamics, durability, design and adaptability has challenged engineers and surgeons
for the last 40 years. Since about 300,000 diseased valves are replaced each year
worldwide, this study is highly relevant to public health. Aortic heart valves are
composed of three distinct layers: fibrosa, ventricularis and spongiosa. These layers are
populated by interstitial cells which actively degrade and remodel the extracellular matrix
to withstand billions of bending cycles without significant wear and tear. Tissue
engineering, the emerging science of combining scaffolds, cells and specific mechanical
and biochemical signals is feasible and holds great promise for treatment of heart valve
disease [1]. Typical approaches include use of biodegradable polymers or decellularized
porcine valves as scaffolds for in vitro cell seeding or in vivo cell infiltration and
remodeling. Valves made by these procedures are either not strong enough to withstand
aortic pressures or cannot be fully repopulated by cells. Recognizing the vital importance
of the three leaflet layers [2], the outstanding hemodynamics of natural valve homografts
[3] and the need for reconstruction of the physiologic valve design, we hypothesized that
combination of four elements can be utilized for tissue engineering of the “ideal” aortic
heart valve: A) Constructs made from partially stabilized collagenous scaffolds, B)
Anatomically analogous 3-D heart valve shapes made from tri-layered structures that
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mimic the native heart valve histo-architecture, C) Autologous multipotent mesenchymal
stem cells for repopulation and remodeling and D) Mechanical cues to induce stem cell
differentiation into valvular cells capable of maintaining matrix homeostasis.

3.2

Specific Aims

Aim 1: Preparation of engineered heart valve scaffolds
Hypothesis: Functional heart valves can be created from layering of stabilized collagen
scaffolds.
Approach: Collagen layers to be used as fibrosa and ventricularis layers were prepared
from decellularized pericardium and lightly cross-linked with penta-galloyl-glucose, a
collagen binding polyphenolic tannin, to allow for delayed biodegradation. For the
spongiosa layer, highly porous collagen scaffolds were prepared from decellularized,
elastase-treated

arteries

and

enriched

with

valve-specific

glycosaminoglycans.

Innovative features include unique engineering of tri-layered valvular structures from
partially stabilized collagen scaffolds specifically designed to replace fibrosa, spongiosa
and ventricularis.

Aim 2: Adhering the three scaffolds used to form engineered heart valves
Hypothesis: Functional heart valves can be created from layering of stabilized collagen
scaffolds and adhered together using a biological glue.
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Approach: To assemble the 3D heart valve structures from layers of collagen scaffolds,
we developed and implemented use of biological adhesives in tissue engineering. After
comparing several adhesives including cyanoacrylate, albumin, gelatin and fibrin-based
glues, we chose to implement a modified albumin/glutaraldehyde adhesive for the
construction of living heart valves and tested for mechanical properties and
biocompatibility.
Innovative features include unique use of a biological glue to assemble the tri-layered
constructs, which has never been described before.

Aim 3: Molding, assembly, and bioreactor testing of tri-layered scaffolds used for
heart valve tissue engineering
Hypothesis: Tissue engineered scaffolds that more closely mimic the 3D ultra-structure
and histo-architecture of a native aortic heart valve will functionally perform similar to a
natural valve.
Approach: Being aware of the vital importance of these layers, we assembled fibrous
and spongy scaffolds in a three-layered structure based on anatomically accurate molds of
aortic valves, in which the spongiosa layer is inserted between two purely collagen
fibrous collagenous layer (fibrosa and ventricularis). Both gluing and layering techniques
were used to create a fully-functional tri-layered construct. Layered collagenous
constructs were tested for functionality in a custom-made bioreactor.
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Innovative features include unique use of molds to form the accurate shape and
corrugations of each leaflet and the assembly of different scaffolds into a tri-layered
construct.

Aim 4: Differentiation of stem cells in tissue engineered heart valves into valvular
interstitial-like cells
Hypothesis: Stem cells exposed to 3D mechanical stimuli should share many similarities
to natural valvular interstitial cells. These studies should indicate that physiologic
mechanical stimuli offered by our 3D tissue engineered heart valve constructs and the
heart bioreactor encouraged differentiation of stem cells into activated valvular interstitial
cells, a much sought-after outcome of cardiovascular tissue engineering. We hypothesize
that conditioning of stem cell-seeded engineered aortic heart valves in a bioreactor will
induce cell differentiation.
Approach: To prove that relevant mechanical can help maturation of tissue
engineered valves, we subjected stem cell-seeded constructs to in vitro cycling in a
bioreactor that is similar to the intra-cardiac environment. We then evaluated cell
differentiation.
Innovative features include the fact that remodeling behavior of stem cells seeded
within tri-layered tissue engineered heart valves has not been studied before.
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4.3

Clinical Significance and Translational Scenario
Cardiovascular malformations are the most common congenital abnormality,

affecting 4 to 6 in 1000 births, with valve defects accounting for up to 30% of these
deficiencies [4, 5]. It is projected that by 2020 at least 1.4 million children will be
affected [6]. A major problem associated with available valve replacements is that no
existing replacements grow with the patient, which could mean a pediatric patient could
need 2-4 valve replacements before 18 years old. Each of these surgeries is associated
with a high operative mortality rate (10-36%) [7]. Furthermore, each operation on
average could cost of a at least $54,000 (US average) [8], placing a large financial burden
not only on the families of those affected but the entire health care industry in general.
Therefore, tissue engineered heart valve replacements hold promise to solve this problem
by creating a living heart valve that can grow with the patient.
Our vision of a potential translational scenario using stabilized collagen scaffolds
and autologous stem cells involves the following steps. After initial diagnosis and
collection of mesenchymal stem cells from the patient, imaging of the diseased heart
valve would provide anatomical coordinates for reconstruction of the heart valve
geometry into solid molds using appropriate software and hardware. Minimizing size
mismatch in implanted heart valve devices is an important aspect of heart valve surgery
[1]. Concomitant with stem cell isolation, valves will be made from decellularized
collagen scaffolds by assembly into tri-layered constructs and then cusps seeded with
autologous stem cells as described in current study. After conditioning in bioreactors for
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1-2 weeks for stem cell pre-differentiation into VIC-like cells, the patient-tailored
engineered heart valve would be surgically implanted back into the patient.

Figure 3.1: Translational scenario for tissue engineered heart valve.
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CHAPTER 4
SCAFFOLD PREPARATION AND CHARACTERIZATION
(AIM 1)

4.1

Introduction
Strategies for heart valve tissue engineering fall into two main categories [3]: a)

preparation of decellularized heart valves by enzyme/detergent methods followed by
repopulation with appropriate cell types in vitro before implantation or relying on host
cells to repopulate and remodel the scaffolds in vivo. This approach has limitations, as
complete valve decellularization was proven difficult to attain and cell repopulation is
difficult due to lack of adequate porosity. A second approach is assembly of synthetic
biodegradable matrices populated by cells and bioreactor conditioning to express
adequate properties before implantation. While this approach seems appealing, the
polymeric matrices lack sufficient mechanical strength and have not withstood the test of
time under arterial pressure [3].
Therefore, a biologically-based scaffold may hold promise. Pericardium has been
widely researched as a biomaterial, including examination of its mechanical and fiber
orientation properties by mapping techniques [4], isolation of pericardial fibroblasts and
analysis of their biosynthetic abilities [5,6] and detailed analysis of its collagen and
proteoglycan components [5,6]. Glutaraldehyde (Glut) fixed bovine pericardium has a
long history of being used in manufacturing of bioprosthetic heart valves, a good record
of implantation in humans, is well characterized mechanically and biologically [1-4], has
been used in development of collapsible percutaneous heart valves [10] and for mitral

79

valve repair [11]. Only recently has decellularized pericardium attracted attention as a
scaffold for tissue engineering [9,12].
Our working premise was that the ideal scaffolds for heart valve applications
should be porous, strong, biocompatible, and conducive to cell repopulation and
remodeling, while maintaining mechanical functions. Our novel strategy relies on use of
stabilized collagen scaffolds that mimic the natural valve fibrous layers, based on
decellularized porcine pericardium [5] and delicate, highly hydrated porous collagen
scaffolds to be used as the middle spongiosa layer. We hypothesized that partially crosslinked collagen scaffolds would fulfill these requirements. To test this hypothesis,
collagen scaffolds were cross-linked with either ultraviolet (UV) light or penta-galloyl
glucose (PGG) and then tested for biodegradation, mechanical properties and in vivo
biocompatibility and remodeling. Their properties were compared to Glut-treated
scaffolds. In the current study we demonstrate that PGG partially cross-links
collagen and preserves the excellent mechanical properties of pericardium. PGGtreated collagen scaffolds do not calcify in vivo and support progressive host cell
infiltration and matrix remodeling, indicating that among the treatments tested, PGG is a
most promising collagen stabilization process for heart valve tissue engineering.

4.2

Materials and Methods

4.2.1 Materials
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose,
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
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(www.omnichem.be). Pure DNA, ribonuclease, glutaraldehyde (50% stock), and
collagenase Type VII from Clostridium histolyticum, were purchased from SigmaAldrich Corporation (St. Louis, MO). Deoxyribonuclease I was from Worthington
Biochemical Corporation (Lakewood, NJ) and Bicinchoninic acid protein assay kits from
Pierce Biotech (Rockford, IL). Electrophoresis apparatus, chemicals and molecular
weight standards were from Bio-Rad, Hercules, CA and elastase was from Elastin
Products Company, Owensville, MO. All other chemicals were of highest purity
available and typically obtained from Sigma Aldrich, St. Louis, MO.

4.2.2 Methods
4.2.2.1 Spongy Scaffold Preparation
For preparation of spongiosa scaffolds, porcine pulmonary arteries obtained from
Animal Technologies Inc. (Tyler, TX) were decellularized. In the first step, tissues were
stored in double distilled water overnight at 4oC to induce hypotonic shock and cell lysis.
After rinsing, tissues were treated with 0.25% Na-Deoxycholate, 0.15% Triton X-100,
0.1% EDTA, 0.02 % NaN3, in 50 mM Tris-HCl buffer (pH 7.8) with mild agitation for
six days at 22ºC, and changes of the solution after three days. After rinsing with doubledistilled water and 70% ethanol to remove detergents, tissues were treated with a
deoxyribonuclease / ribonuclease mixture (360 milliunits/ml for each enzyme) at 37ºC for
24 hours to fully digest away nucleic acids. This was followed by rinsing twice with
double distilled water and incubation in ultra pure elastase (10 Units/ml) in 50 mM Tris
buffer, 1 mM CaCl2, 0.02% NaN3 (pH=8), at 37oC for six days with mild agitation.

81

Elastase was replaced with fresh solution after three days. Tissues were rinsed in double
distilled water at 22ºC until Bicinchoninic acid protein assay revealed undetectable levels
of soluble proteins. Scaffolds were finally rinsed with 70% ethanol and then stored in
sterile saline supplemented with 0.02% NaN3 at 4oC.

4.2.2.2 Spongy Scaffold characterization
For histology, paraffin-embedded samples were stained with Hematoxylin and
Eosin (H&E) and Masson’s trichrome (n=6 slides per group per stain). To detect Gal we
performed lectin histochemistry using biotinylated Griffonia simplicifolia lectin as the
primary reactant, followed by ABC-peroxidase complex and DAB detection with
Hematoxylin counterstaining [6]. Scanning electron microscopy (SEM) sample
preparation was performed according to standard procedures [7] and imaged on a Hitachi
S4800. To test for cytocompatibility, rat dermal fibroblasts were seeded (105 cells per
cm2) onto sterile scaffolds and cell viability and proliferation evaluated weekly for up to
5 weeks using LIVE/DEAD® stain (Molecular Probes, Carlsbad, CA) and CellTiter 96®
AQueous One Solution Cell Proliferation Assay MTS (Promega, Madison, Wisconsin) as
per manufacturers’ directions. Samples were also stained with 4-6 Diamidino-2phenylindole (DAPI) blue fluorescent nuclear stain.
Total genomic DNA was extracted and purified from scaffolds and from fresh
arteries as controls (n = 3 per group), using a Fibrous Tissue DNeasy Kit (Qiagen,
Valencia, CA), subjected to agarose/ethidium bromide gel electrophoresis followed by
densitometry using Gel-Pro Analysis Software (MediaCybernetics, Silver Spring, MD).
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Water content was calculated gravimetrically from weights obtained before and after
freeze-drying of fresh artery and scaffold samples (n = 6 per group). Glycosaminoglycan
(GAG) content was analyzed by full digestion of fresh tissue and scaffolds with protease
K followed by reaction of released GAGs with 1,9-dimethylmethylene blue dye and
colorimetry [8, 9].

4.2.2.3 Fibrous Scaffold preparation
Fresh adult swine pericardial sacs obtained from Animal Technologies Inc.
(Tyler, TX) were cleaned, rinsed in sterile saline, cut into strips, and then decellularized
as follows. In the first step, tissues were stored in double distilled water overnight at 4oC
to induce hypotonic shock and cell lysis. After rinsing, tissues were treated with 0.25%
Na-Deoxycholate, 0.15% Triton X-100, 0.1% EDTA, 0.02 % NaN3, in 50 mM Tris-HCl
buffer (pH 7.8) with mild agitation for six days at 22ºC, and changes of the solution after
three days. After rinsing with double-distilled water and 70% ethanol to remove
detergents, tissues were treated with a deoxyribonuclease / ribonuclease mixture (360
milliunits/ml for each enzyme) at 37ºC for 24 hours to fully digest away nucleic acids.
This was followed by rinsing twice with double distilled water and incubation in ultra
pure elastase (10 Units/ml) in 50 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3 (pH=8), at
37oC for six days with mild agitation. Elastase was replaced with fresh solution after
three days. Tissues were rinsed in double distilled water at 22ºC until Bicinchoninic acid
protein assay revealed undetectable levels of soluble proteins. Scaffolds were finally
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rinsed with 70% ethanol and then stored in sterile saline supplemented with 0.02% NaN3
at 4oC.

4.2.2.4 Fibrous Scaffold characterization
For histological evaluation, paraffin-embedded samples were stained with
Hematoxylin and Eosin for general morphology and confirmation of cell removal and
with Verhoeff van Gieson to confirm removal of elastin (n=6 slides per group per stain).
Digital pictures were taken of Hematoxylin and Eosin stained samples (n=2 slides per
group) at 400X magnification and open spaces (pores) between intact collagen fibers
were measured using AxioVision Release 4.6.3 digital imaging software (Carl Zeiss
MicroImaging, Inc. Thornwood, NY). To further validate decellularization, total genomic
DNA was extracted and purified from collagen scaffolds and from fresh pericardium as
controls (n=3 per group), using a Fibrous Tissue DNeasy Kit (Qiagen, Valencia, CA)
following manufacturers’ instructions. DNA samples were subjected to agarose
electrophoresis alongside pure DNA standards (10-100 ug/ml) followed by densitometry
using Gel-Pro Analysis Software (MediaCybernetics, Silver Spring, MD). DNA levels
were calculated from the standard curve and normalized to initial tissue wet weight. To
detect Gal we performed lectin histochemistry using biotinylated Griffonia simplicifolia
lectin as the primary reactant, followed by ABC-peroxidase complex and DAB detection
with Hematoxylin counterstaining [6].
To test for presence of soluble proteins, scaffolds and fresh pericardial samples
(n=2 per group) were pulverized in liquid N2, proteins extracted in an extraction buffer
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(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium
Deoxycholate, 0.1% SDS, pH 7.4, with protease inhibitor cocktail) and protein content
determined using BCA assay. Samples normalized to initial dry weight were analyzed for
detergent-soluble proteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis
followed by silver staining (SilverSnap, Pierce Biotech, Rockford, IL). For detection of
matrix metalloproteinase 2 (MMP-2) same protein extracts were analyzed by an MMP-2
ELISA kit (Amersham Biosciences, Piscataway, NJ) and results normalized to mg
soluble protein.
Chemotaxis assays were conducted using a Boyden chamber (NeuroProbe,
Gaithersburg, MD) and a polycarbonate filter with 8 µm diameter pores, as per
manufacturers’ instructions. Soluble collagen peptides (matrikines) were prepared by
treatment of decellularized porcine pericardium with collagenase (10 U/ml) for 24 hours.
The supernatant was filtered through Microcon YM-3 centrifugal devices and peptides
smaller than 3 kDa were collected in the flow-through for chemotaxis assays. Rat aortic
fibroblasts (10x105/well, prepared in house by an explant technique) suspended in
DMEM/0.1% bovine serum albumin were used in these tests; undiluted Fetal Bovine
Serum (100%) was used as a positive control and DMEM/0.1% bovine serum albumin as
the negative control. Cells migrated for 4 hours at 37ºC and 5% CO2. After incubation,
the non migrated cells were removed with a wiper blade and the filter fixed and stained
using a DiffQuick® kit (Dade Behring Inc, Newark, DE) dried, and screened for
migrated cells using an inverted microscope. Results were reported as negative (0-2 cells
per 10x field), slightly positive (2-10 cells), or positive (> 10 cells).
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4.2.2.5 Evaluation of PGG cross-linking and stability
To evaluate the cross-linking efficiency of PGG, fibrous scaffolds were treated
with different concentrations of PGG (0%, 0.1%, 0.15%, and 0.3%) and leaching of PGG
was tested. Briefly, ½” diameter circles of decellularized pericardium were cut using a
core borer. The circles were then placed in PBS. For a long wash procedure, the circles
were next placed in corresponding PGG concentrations for fixation (for 24 hrs.). The
circles were then removed from PGG after 24 hrs., and placed in sterile PBS w/ 0.02%
azide (making sure to keep groups separated) and shaken on an oscillating shaker at room
temp. The wash was removed and replaced with new PBS every day for 5 days. At the
end of the long wash procedure, circles designated for a short wash were placed in
corresponding concentrations of PGG (as for long wash). All circles were then washed
2X in sterile PBS by gentle inversion, then place circles in 70% ethanol for 10 mins. in
sterile 50 ml conical tube.. The circles were then washed 2x in sterile PBS by gentle
inversion in sterile 50 ml conical tube. The circles, keeping differing concentrations of
PGG-fixed circles separated, were placed in 50/50 FBS/DMEM (in sterile 50 ml conical
tubes) for 24 hrs in an incubator at 37°. The disks were then removed from 50/50 tubes
and placed in new tubes with glycine for ~2hrs. The disks were then removed from
glycine and each disk placed in a well of a 12-well plate (NOT tissue culture treated).
Approximately 50,000 rat aortic fibroblasts were placed directly to top of each circle. The
plate was placed in an incubator @ 37° for 2 hrs. Live/Dead and MTS assays were then
preformed on the samples.
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Next, fibrous scaffolds were treated with different concentrations of PGG (0%,
0.0375%, 0.075%, 0.10%, and 0.15%, n=6 per concentration) and exposed to collagenase
to test degradation properties. The long wash procedure was followed as above. At the
end of the washes, the circles were then placed in collagenase (as described in section
4.2.3.5) for 7 days.

4.2.2.6 Properties of cross-linked fibrous collagen scaffolds
Scaffolds were prepared as above and treated with one of three methods: (a)
Glutaraldehyde (Glut), (b) Penta-galloyl-glucose (PGG), and (c) Ultraviolet light (UV) ,.
For UV treatment, scaffold samples were first dried flat in sterile conditions (2 days in a
cell culture hood at 22ºC), then UV-treated in a Spectrolinker XL-1000 UV cross linker
(Spectronics Corporation, Westbury, NY) at optimal density (1200 x 100 µJ/cm2) for 30
minutes. Samples were stored dry at 4oC until use. For Glut fixation, wet scaffold
samples were incubated in 0.6% glutaraldehyde in 50 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES) buffered saline (pH=7.4) overnight at 22ºC and
subsequently rinsed and stored in sterile saline. For PGG fixation, the scaffolds were
incubated with 0.15% PGG in 50 mM phosphate buffer (pH 5.5) containing 4%
isopropanol, for 24 hours at 22oC, rinsed and stored in sterile saline.
To evaluate cross-linking efficacy, scaffold samples were tested for resistance to
collagenase. Treated and untreated samples (n=18 per group) of about 15 x 5 mm were
rinsed 3 times in ddH20 at 22ºC and lyophilized to record dry weight. Each sample was
then incubated separately with 1 ml of collagenase (6.25 units/ml) dissolved in 100 mM
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Tris buffer, 1 mM CaCl2, 0.02% NaN3 (pH=7.8) for 1, 2, and 7 days at 37ºC with mild
agitation. At each time point, 6 samples from each group were rinsed 4 times with ddH20
by centrifugation (12,000 rpm, 1.5 minutes, 18ºC) after which the samples were
lyophilized to obtain dry weights after collagenase, and percent of digested tissue was
calculated.
Three specimens from each group of (1) control (no fixation), (2) Glut, (3) PGGtreated scaffolds, and (4) UV were also subjected to thermal denaturation temperature
(Td) analysis by Differential Scanning Calorimetry (DSC-131, Setaram Instrumentation,
Caluire, France). Specimens were tested at a heating rate of 10˚C/min from 20˚C to
110˚C in a N2 gas environment. Td, a well known indicator of collagen cross-linking was
defined as the temperature at the endothermic peak [13].

4.2.2.7 In vivo evaluation of fibrous scaffolds
Male, juvenile Sprague-Dawley rats (weighing around 50 grams, from Harlan
Laboratories; Indianapolis, IN) were sedated with acepromazine (0.5 mg/kg, Ayerst
Laboratories, Rouse Point, NJ) and maintained on 2% isoflurane during surgery. A small
transverse incision was made on the backs of the rats and two subdermal pouches (one
superior and one inferior to the incision) were created. Samples were prepared for
implantation by overnight soaking in sterile saline. Controls (no cross-linking), Gluttreated, PGG-treated, and UV-treated scaffold samples (as prepared above) were
implanted into the subdermal pouches (n=8 implants per group per time point) and
incisions closed with surgical staples. After surgery the rats were allowed to recover and
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permitted free access to water and food. The animal protocol was approved by the
Animal Research Committee at Clemson University and NIH guidelines for the care and
use of laboratory animals (NIH publication #86-23 Rev. 1996) were observed throughout
the experiment.
The rats were humanely euthanized by CO2 asphyxiation at 1, 3, and 6 weeks
after surgery and samples retrieved for analysis. A small section of each explant with its
associated capsule was maintained for histological evaluation. The remainder of explants
were cleaned free of capsule rinsed in saline and then divided for DNA, calcium and
matrix metalloproteinase (MMP) analysis.
For histology samples were placed in formalin and paraffin sections (5 µm) were
stained with Hematoxylin and Eosin \ for general morphology. For identification of
infiltrating cell types, samples tagged for immunohistochemistry were placed in formalin
[17,18] and paraffin-embedded. Sections (5 µm) were exposed to 0.1% Proteinase K
solution (25 units/500 ml, from Qiagen DNeasy Tissue Kit) in Tris Buffer Saline (TBS),
pH=7.5 at 22ºC for 30 seconds. Endogenous peroxidases were blocked with 0.3% H2O2
in 0.3% normal sera (Vectastain Elite ABC kit for rabbit IgG, Burlingame, CA). Sections
were immunostained using mouse anti-rat monoclonal antibodies to macrophages (1:200
dilution, Chemicon, Temecula, CA), vimentin (1:500 dilution, Sigma, St. Louis, MO) and
Prolyl-4-hydroxylase (1:200 dilution, Chemicon, Temecula, CA) at 22ºC for 1 hour. To
minimize cross reactivity, rat-absorbed biotinylated anti-mouse IgG was used in place of
biotinylated secondary antibody provided with the staining kit. Negative staining controls
were performed with the omission of the primary antibody. Diaminobenzidine
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tetrahydrochloride peroxidase substrate kit was used to visualize the specific staining
(Vector Laboratories, Burlingame, CA) and sections were lightly counter-stained with
Hematoxylin. As positive controls we stained paraffin sections from rat spleen
(macrophage control) and rat skin (fibroblast control) in parallel with the explant
sections.
To visualize phenol groups within PGG-treated samples we used an iron-based
histology stain [19] [10][10][9][12][12]. Briefly, tissues were stained en-bloc with FeCl3,
embedded in Tissue Tek OCT compound (Sakura Finetek, USA Inc., Torrance, CA) and
six micrometer thick sections counterstained with Light green. PGG appears brown with
this staining.
For DNA analysis explants (n=3 per group per time point) were weighed and then
subjected to DNA extraction and purification using the Qiagen Kit and DNA content
evaluated by agarose gel electrophoresis followed by densitometry as described above.
Explanted samples (n=4 per group per time point) were rinsed in saline, lyophilized to
obtain dry weight and individually hydrolyzed in 6N HCl, dried under nitrogen, and
reconstituted in 1.0 ml of 0.01 N HCl. Calcium content was then measured using atomic
absorption spectrophotometry as described before [20,21].
For matrix metalloproteinase detection, proteins were extracted in 50 mM Tris,
1% Triton X-100, 0.1% SDS, 1% Deoxycholate, 150 mM NaCl, with protease inhibitor
mixture, pH=7.4 buffer and protein content determined using the Bicinchoninic acid
assay as described before [19]. Samples were subjected to gelatin zymography using 6 µg
of protein per lane alongside molecular weight standards [22]. Intensity of MMP bands
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(white bands on dark background) were evaluated by densitometry using Gel-Pro
Analysis Software (MediaCybernetics, Silver Spring, MD) and expressed as relative
density units (RDU) normalized to protein content.
Glycosaminoglycan content in explanted tissues was determined by a
dimethylmethylene blue assay as described before [13]. Briefly, a sample of extracted
protein (described above for MMP assay) was digested with papain and released
glycosaminoglycans were incubated with dimethylmethylene blue reagent and OD read at
525nm. Glycosaminoglycan content was calculated from a standard curve of pure
chondroitin sulfate (0-25 ug/ml) and values expressed as µg/mg protein.

Statistics
Results are represented as means ± the standard error of the mean (SEM). Statistical
analysis was performed with one way Analysis Of Variances (ANOVA) and results were
considered significantly different at p<0.05.

4.3

Results

4.3.1 Scaffold Characterization
4.3.1.1 Spongy Scaffold characterization
Highly hydrated, collagen scaffolds to be used as valvular spongiosa were
prepared from porcine pulmonary aorta by decellularization and removal of elastin.
Histology showed complete cell and elastin removal from the pulmonary aorta (Figure
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4.1), leaving behind a porous collagen scaffold with pore sizes ranging between 20 and
100 microns.

Figure 4.1: Histology of spongy collagen scaffolds. (A, C) fresh porcine pulmonary
artery and (B, D) decellularized pulmonary artery scaffolds were stained with H&E stain
(A, B), Trichrome stain (C, D, collagen blue, cells dark pink).
Histochemical staining showed the spongiosa scaffold lacked Galα antigen.
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Figure 4.2: Histology of spongy collagen scaffolds. (A) fresh porcine pulmonary artery
and (B) decellularized pulmonary artery scaffolds stained with GS lectin for Gal antigen
(A & B, dark brown = positive staining). Bars are 50 m.

Analysis of spongiosa scaffold by contrast phase microscopy and SEM revealed a
3-D matrix composed of insoluble collagen fibrils of 1-2 microns in diameter assembled
into larger fibers and wavy bundles.

Figure 4.3: Properties of spongiosa scaffolds. (A,B) Phase contrast micrographs of fresh
scaffolds. Bars are 100 m
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Figure 4.4: Properties of spongiosa scaffolds. (A) SEM image of scaffold surface.

The spongy scaffold was fully degradable by collagenase in vitro (not shown) and
supported fibroblast growth and proliferation for up to 5 weeks (Figure 4.5).

Figure 4.5: Properties of spongiosa scaffolds. (A, B) Cytocompatibility testing with
fibroblasts stained with Live/Dead stains (live cells green, dead cells red) and
DAPI nuclear stain (light blue), respectively. Bars are 100 m.
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Semi quantitative DNA analysis revealed almost complete cell removal.
Specifically, levels of high molecular weight genomic DNA were significantly reduced
and there was no sign of morphologically identifiable cells by histology, thus we
considered the scaffolds acellular. As can be seen on the agarose gels (Figure 4.6),
minute amounts of low molecular weight DNA fragments may have been trapped in the
scaffolds but we did not consider this a sign of cell presence.
Macroscopically, spongiosa collagen scaffolds appeared as white, highly
hydrated matrices which, when compared to the native tissue, occupied almost 4 times
larger volumes than the original artery while maintaining the original shape and more
than 90% water (Figure 4.7).

Figure 4.6: Properties of spongiosa scaffolds. (A) Shows agarose/Ethidium bromide
electrophoresis, of extracted DNA, alongside pure DNA standard while (B) quantifies
DNA content of fresh and decellularized scaffolds
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Figure 4.7: Properties of spongiosa scaffolds. Water content of fresh and
decellularized scaffolds; insert shows macroscopic aspects of 10 x 10 mm arterial
tissue samples before (left) and after (right) decellularization/elastase treatment.

Glycosaminoglycans (GAGs) were also analyzed in tissues and scaffolds. As
compared to fresh pulmonary artery (14.6 ug GAGs/mg dry), the spongiosa layer
contained about 8.5 ug GAGs/mg dry, which is about 3 times lower than values reported
in the literature for the whole aortic cusp (25 ug GAGs/mg dry). To date we have no
knowledge of precise GAG content of the spongiosa layer alone in native aortic heart
valves.

4.3.1.2 Fibrous Scaffold Characterization
Our technique for decellularizing porcine pericardium involved hypotonic shock,
detergent extractions, nuclease digestions and elastase treatment. Results showed that an
acellular structure of histologically intact pure wavy collagen fibers with long inter-fibril
open spaces (pores) of 8-30 microns in diameter was obtained (Figure 4.8 (A-D)).
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Figure 4.8: Histology of fibrous scaffolds. (A) H&E staining of acellular scaffold
showing wavy collagen fibers interspersed with pores. Note complete lack of cell
staining, as compared to native tissue (B) where cells are outlined by black arrows. (C)
VVG staining showed fine elastin fibers (black arrow) throughout the native pericardial
tissue, which were completely removed (D) by elastase treatment

Figure 4.9: Histology of spongy collagen scaffolds. (A) fresh porcine pericardium, and
(B) decellularized pericardium scaffolds stained with GS lectin for Gal antigen (A & B,
dark brown= positive staining). Bars are 50 m.
Histochemical staining showed the fibrous scaffold lacked Galα antigen.
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The large majority of the fibers were insoluble since strong detergent extractions
yielded very few extractable proteins as evidenced by electrophoresis and silver-staining
(Figure 4.10).

Figure 4.10: Properties of fibrous scaffolds. Presence of SDS-soluble proteins in fresh
pericardium and acellular collagen scaffolds was evaluated by SDSPAGE and silver
staining

Decellularization was confirmed by DNA extraction and evaluation using agarose
gel electrophoresis (Figure 4.11 (A)) followed by densitometry (Figure 4.11 (B)), which
showed more than 94% reduction in DNA content.
Furthermore, histochemical staining showed that both the fibrous scaffold
(derived from pericardium) as well as the spongiosa scaffold lacked Galα antigen.
ELISA measurements showed significantly lower levels of remnant MMP-2 activity in
scaffolds as compared to fresh pericardium (Figure 4.12).
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Figure 4.11: Properties of fibrous scaffolds. (A) Agarose/ethidium bromide gel
electrophoresis of DNA extracted from fresh pericardium and the acellular collagen
scaffolds; (B) densitometry of DNA bands in (A)

Figure 4.12: Properties of fibrous scaffolds. ELISA for MMP-2 in fresh pericardium and
the acellular collagen scaffolds.
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Fibroblasts exhibited a strong positive chemotaxis toward collagen peptides obtained
from decellularized pericardium (Figure 4.13) suggesting that scaffold degradation
products could encourage repopulation by acting as matrikines.

Figure 4.13: Characteristics of acellular porcine collagen scaffolds: Chemotaxis of
fibroblasts towards collagen peptides obtained from acellular pericardium; inset in (A)
shows a cell undergoing mitosis after chemotaxis, (B) positive chemotaxis control, (C)
negative control.

4.3.1.3 Evaluation of PGG cross-linking and stability
To evaluate the cross-linking efficiency of PGG, fibrous scaffolds were treated
with different concentrations of PGG ( 0%, 0.1%, 0 .15%, and 0 .3%) and leaching of
PGG was tested. There was no significant difference in cell viability between the 3
concentrations tested as given by MTS assays (Table 4.1)
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Table 4.1

However, there is a noticeable difference in the cell viability on each of the scaffolds
when the Live/Dead assay was used, with the 0.15% scaffold being the highest
concentration with viable cells. The 0.3%-fixed scaffold showed no live cells upon
evaluation (Live/Dead shown for 0.15%-treated scaffold).

Figure 4.14: Phase contrast (A) and Live/Dead (B) of 0.15%-fixed scaffold that was
washed over a weeks time.
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Figure 4.15: Collagenase study with scaffolds washed for a week.

The PGG, fibrous scaffolds were then treated with different concentrations of PGG (0%,
0.0375%, 0.075%, 0.10%, and 0.15%) based on leaching studies above and washed over
a one week time, then exposed to collagenase to test degradation properties.
Results showed there was a significant difference between 0.10% and 0.15%
PGG-fixation and all other concentrations, as well as there is a significant difference
between 0.10% and 0.15%, therefore the 0.10% and 0.15% concentrations prevent
degradation of the scaffold more effectively than the other concentrations.

4.3.1.4 Properties of cross-linked fibrous collagen scaffolds
Collagen scaffolds were treated with Glut, a known protein cross linker [11],
PGG, a compound known to interact with Proline-rich proteins such as collagen [12], and
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UV-light. Samples were then tested in vitro for resistance to collagenase, mechanical
properties and thermal denaturation characteristics. Collagenase was used as an
accelerated model for degradation and a widely accepted test that reveals extent of
collagen cross-linking [13, 14]. Results showed that control, untreated scaffolds were
almost completely digested by collagenase in 1-2 days (Figure 4.16), suggesting that
decellularized porcine pericardium is highly biodegradable.

Figure 4.16: Resistance to collagenase of treated collagen scaffolds; a time-course study.
Percent mass loss after collagenase treatment is shown for untreated scaffolds (control)
and for UV, Glut and PGG-treated scaffolds. Control values were all significantly higher
than other groups. *ANOVA statistical significance between groups.

Expectedly, Glut-treated collagen was highly resistant to collagenase at all time points,
indicating that glutaraldehyde fixation of collagen is very strong and practically
irreversible. PGG-treated collagen scaffolds exhibited excellent resistance to collagenase
at 1 and 2 days with a slight but significant (p<0.05) increase in mass loss at 7 days
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(almost 15% degradation by collagenase). These data suggest that PGG and UV
treatment are good short-term collagen fixatives.
Differential scanning calorimetry analysis showed Td values of 76.9±1.0oC
(mean ±SEM) for control scaffolds, 86.9±0.2oC for Glut and 78.2±0.6oC for PGGtreated scaffolds. All values were statistically different among groups (ANOVA, p<0.05),
with the exception of PGG vs. control (p=0.454).

4.3.1.5 In vivo biocompatibility studies of fibrous scaffolds
To study biocompatibility and cell repopulation potential of our scaffolds we
implanted samples subdermally in juvenile rats and analyzed them at 1, 3, and 6 weeks
post-implantation. H&E staining (Figure 4.17) revealed a time dependent increase in cell
infiltration in control (untreated) scaffolds associated with visible collagen fiber
degeneration, confirming the fact that the collagen scaffold is degradable in vivo. Glutfixed collagen scaffolds showed good collagen fiber preservation and significantly less
cell infiltration (Figure 4.17 (C)) validating the fact that Glut-treated collagen is not an
ideal substrate for cell-mediated remodeling.
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Figure 4.17: Histological analysis of subdermally implanted scaffolds. Representative
H&E micrographs from 3 weeks samples showing (A) pre-implant collagen scaffolds,
(B) explanted control scaffolds, (C) explanted Glut-treated scaffolds, and (D) explanted
PGG-treated scaffolds. Black arrows point to cells present within implants.

PGG-treated scaffolds (Figure 4.17 (D)) exhibited clear signs of collagen fiber
degradation, visibly less than control untreated collagen and more than Glut-fixed
collagen. Similarly, larger numbers of infiltrating cells were found in PGG-treated
collagen as compared to Glut-fixed collagen, but less than in untreated controls. Cell
infiltration in PGG treated scaffolds increased with time, clearly showing that PGG
treatment is not cytotoxic. UV-treated scaffolds exhibited a dramatically collapsed
structure, practically impenetrable to cells at all time points (Figure 4.18).
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Figure 4.18: Histological analysis of subdermally implanted scaffolds. Representative
H&E micrographs from 3 weeks samples showing UV-treated scaffold before (A) and
after implantation (B). Black arrows point to cells present within implants.

Histology data was confirmed by quantitative DNA analysis. Despite considerable
biological variability among samples, data showed significant DNA present at all time
points in most tissues, with less DNA present in Glut-fixed tissues at 3 weeks (p<0.05).
Comparative analysis of 6 week vs. 3 week data revealed that DNA content apparently
reached a plateau after 3 weeks, indicating that cell infiltration is complete within this
time frame in subdermal implants (Table 4.2).
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DNA levels in explanted collagen scaffolds
Samples

DNA content (g / gram wet weight ± SEM, n=3)
1 week

Control

910 ± 130b

3 weeks

6 weeks

1459 ± 185

961 ± 373

UV

1108 ± 145

3258 ± 1102a, b

2179 ± 488

Glut

1121 ± 318

578 ± 21a, b

1396 ± 341

PGG

2662 ± 538

2287 ± 172

642 ± 128a

a

statistical significance among time points within each fixation group (p<0.05).
statistical significance among groups at each time point (p<0.05).
Table 4.2
b

A large majority of cells infiltrating collagen scaffolds were vimentin-positive
cells resembling fibroblasts (Figure 4.19 (A)). Cell density apparently increased with
time of implantation for control and PGG scaffolds, while cell infiltration in Glut-fixed
scaffolds was significantly reduced at all time points. Infiltrating cells were also positive
for proline-hydroxylase, an enzyme involved in collagen synthesis (Figure 4.19 (B)).
Macrophage infiltration was very scarce in all implants at all time points (Figure 4.19
(C)).
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Figure 4.19: Immunohistochemical identification of infiltrating cells. a) Vimentin stain
showing extensive fibroblast-like infiltrating cells in all implant groups at 1 week (1w), 3
weeks (3w) and 6 weeks (6w) after implantation. b) Proline-hydroxylase
immunohistochemical staining; arrowheads point to positively stained cells. c) Specific
staining showing very few macrophages (arrowheads). Inset in (c) shows macrophage
staining of rat spleen sections used as a positive control. Sections were counterstained
with hematoxylin (nuclei dark blue). Bars are 50 microns in all micrographs.

Calcium analysis in explanted scaffolds (Table 4.3) revealed significantly high
levels in Glut-fixed and UV-treated collagen while control, untreated collagen scaffold
samples, as well as PGG-treated scaffolds did not accumulate any significant amounts of
calcium, indicating that despite effective collagen stabilization, PGG treatment may not
induce collagen calcification while UV treatment induces significant calcification of the
scaffolds.

Calcium levels in explanted collagen scaffolds
Samples

Ca content (g / mg dry weight ± SEM, n=4 )
1 week

3 weeks

6 weeks

1.4 ± 0.5

1.2 ± 0.3

0.5 ± 0.1

UV

32.6 ± 17.5b

97.3 ± 17.2a, b

121.9 ± 11.7a, b

Glut

2.8 ± 1.4

5.4 ± 3.8

4.6 ± 2.6

PGG

1.4 ± 0.4

1.5 ± 0.5

1.1 ± 0.2

Control

a

statistical significance among time points within each fixation group (p<0.05).
statistical significance among groups at each time point (p<0.05)
Table 4.3
b
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Phenol staining showed tight binding of PGG to collagen (Figure 4.20 (A)) which
appeared to be maintained even after 3 weeks of subdermal implantation (Figure
4.20(B)) suggestive of stable PGG-collagen interactions.

Figure 4.20: Histological analysis of subdermally implanted scaffolds. (A) Phenol
staining showing collagen-bound PGG (brown) before implantation and (B) 3 weeks after
subdermal implantation. Insert in (A) represents phenol staining of a negative control
(scaffold not treated with PGG).

Matrix metalloproteinase (MMP) activity was measured in explants from all time
points using gelatin zymography (Figure 21). Two major proteases were identified in
tissue extracts, namely MMP-9 (migrating at around 90-95 kDa) and MMP-2 (65-80
kDa). Band intensity was measured for each sample (normalized to protein content) and
represented as relative density units or RDU (Figure 21). Similar trends were observed
for MMP-9 and MMP-2, i.e. high enzyme levels at 1 and 3 weeks, leveling off at 6
weeks. Activity of MMP-2 was about 10 times higher in all samples as compared to
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MMP-9. The total MMP enzyme activity distribution resembled that of the DNA content.
In addition, glycosaminoglycan levels within all implant groups showed a mean overall
value of 175 +/- 30 ug per mg extracted protein, but without showing statistical
significance among treatment groups and time points (p>0.05). Overall results suggest
the presence of cells actively involved in matrix remodeling.

Figure 4.21: MMP activities in explanted scaffolds. Densitometry of active MMP bands
are expressed as relative density units (RDU) normalized to protein content. MMP-9 (A)
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and MMP-2 (B) were identified from their relative migration on gelatin containing 10%
polyacrylamide gels (insets show representative zymograms).

4.4

Discussion
It is our premise that the outstanding performance of allografts is mainly due to

the fact that they very closely mimic the natural valve anatomy. Since collagen represents
the predominant component of heart valves we hypothesized that use of collagen
membranes engineered to mimic the native anatomical heart valve structure would serve
as an effective approach to heart valve tissue engineering.
It is vital that implanted heart valves function immediately after implantation but
also support host cell infiltration and remodeling. It is our working hypothesis that such
properties can be achieved by development of partially cross-linked collagen scaffolds.
Full cross-linking would reduce cell infiltration and remodeling capacity to a minimum
and thus may prevent tissue regeneration. Conversely, uncross-linked scaffolds may
degrade too rapidly after implantation and thus reduce functionality of the tissue
engineered heart valves. Moderately cross-linked scaffolds would allow for slow but
sustained cell infiltration with temperate remodeling of the scaffold, without alterations in
valve properties. In current study we evaluated non-Glut fixation methods such as UV
light and PGG treatments of acellular porcine pericardium for development of novel
scaffolds for heart valve tissue engineering.
In current study we illustrated development of a new scaffold to be used as a
spongiosa layer for heart valve tissue engineering. The middle spongiosa layer,
composed primarily of glycosaminoglycans (GAGs) and collagen, is easily deformed in
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the presence of shear forces and cushions shock during the valve cycle and is not readily
compressed. This resistance to compression during bending aids in cuspal mechanics by
preventing buckling during flexion (systole), which could result in overall cuspal damage
[15]. To obtain pure collagen scaffolds with constant and predictable composition and
properties, porcine pulmonary artery was successfully decellularized using hypotonic
shock, detergent extraction and nuclease digestion. The scaffold was further treated with
elastase. Removal of elastin created supplementary pores for cell infiltration and assisted
with tissue decellularization. The spongiosa has a gelatinous consistency, due in large
part to the hydrophillicity of the GAG molecules. This novel acellular scaffold composed
of collagen and GAGs was highly hydrated, porous and hydrophilic, showed good
preservation of matrix components, lacked Galα antigens and supported in vitro cell
repopulation. Enhanced scaffold characterization could be obtained by more extensive
ultra structural analysis of collagen and elastin fiber integrity, GAG components and
presence of minute cell debris [16, 17].
Porcine pericardium was successfully decellularized using hypotonic shock,
detergent extraction and nuclease digestion. This is an accepted decellularization
approach for fibrous connective tissues [29]. Since pericardium contains about 10%
elastin, we added an extra step, elastase treatment, to fully remove elastin, increase
porosity and make mechanical properties more homogenous. Histology, DNA and protein
analysis showed that decellularization was complete and the scaffold was predominantly
composed of insoluble collagen fibrils devoid of inter-fibrillar matrix or cells.
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To evaluate cross-linking possibilities, we treated decellularized pericardium with
UV, PGG and Glut and compared their properties with untreated scaffolds as controls.
Native, untreated scaffolds degraded quickly in vitro and in vivo, were rapidly invaded
by host cells, showed signs of remodeling and lack of calcium deposition. UV treatment
had the most dramatic effects on collagen scaffolds including irreversible and aggressive
changes in tissue structure, full collapse of the porous configuration and significant
changes in mechanical properties. UV treated scaffolds appeared to have been partially
cross-linked because they exhibited initial resistance to collagenase in the first 1-2 days
of exposure to the enzyme, subsequently losing more than 1/3 of its mass after 7 days in
collagenase.
Upon implantation, UV treated collagen scaffolds were not infiltrated by
host cells, calcified massively and adhered strongly to their fibrous capsules.

The

mechanisms of UV-induced collagen cross-linking are thought to include radical
mediated alterations in aromatic amino acids [18]. These changes may be responsible for
observed in vitro resistance to collagenase. It is not clear at this point how UV treatment
induces collagen calcification but we speculate that it does so through dramatic changes
in molecular structure and ultra structure, including loss of fibrillar architecture [19].
Although this cross-linking procedure appears advantageous for tissue engineering
applications, the propensity of UV treated collagen towards calcification needs to be
further addressed. Notably, subdermal implantation in juvenile rats serves as a model for
calcification [34] as well as for degradation of matrix components and remodeling
[35,36].
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Glut

treatment

effectively stabilized

decellularized

pericardium

against

collagenase, an expected feature known in the bioprosthetic heart valve field [2].
Moreover, Glut-fixed scaffolds exhibited typical mechanical properties and high Td (as
compared to native collagen). Upon implantation, Glut-fixed collagen calcified to some
extent, but not to levels reported for bioprosthetic heart valves analysis, where Glut-fixed
pericardium showed calcification levels of about 100 g/mg [30]. This may be because of
absence of pericardial cells which are presumably the initial calcification nucleation sites
[31]. Cell infiltration was noted to occur to some extent in Glut-fixed scaffolds but cell
numbers did not increase with time and, despite the fact that some infiltrating cells were
fibroblast-like cells expressing MMPs, Proline-hydroxylase and glycosaminoglycans; it is
unlikely that these scaffolds will undergo remodeling after implantation.
PGG treatment revealed substantial initial collagen stabilization versus the action
of collagenase in vitro, with the potential for reversibility. It should be noted that the in
vitro collagenase system is an accelerated model for degradation as collagenase activities
in vivo are not expected to be so harsh [32]. Differential scanning calorimetry analysis
showed a slightly higher Td when compared to native scaffold and lower than Glut (but
not statistically different) partially confirming collagenase results. This phenomenon of
tissue resistance to collagenase in the absence of high Td values was reported previously
for the Photofix stabilization procedure [33]. Mechanical properties of PGG-treated
scaffolds were similar to untreated and Glut treated samples except for a relatively higher
hysteresis (data not shown). Despite effective collagen stabilization, PGG treated
collagen did not calcify in vivo, suggesting that the nature of the cross-linker may
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determine the outcome of collagenous implants. Host cells infiltrated implants relatively
rapidly indicating that PGG-treated collagen is not cytotoxic. Moreover these fibroblastlike cells secreted MMPs, expressed Proline-hydroxylase and secreted GAGs and thus
may exhibit true potential for remodeling. Because long-term, adequate control of local
inflammation

and

MMP

activities

may

be difficult to achieve and may be

accompanied by adverse side effects, such as failure of the implant, [20] demonstrating
that the tissue has potential to remodel, as indicated by the types of cells infiltrating over
the time course of the in vivo study, further supports the notion that PGG may be a safe
and effective collagen stabilizing agent.
Mechanisms of PGG-induced collagen stabilization are not fully understood. PGG
is a naturally derived polyphenol characterized by a D-glucose molecule derivatized at all
five hydroxyl moieties by gallic acid, i.e. 3,4,5-trihydroxybenzoic acid (Fig. 2b).
Polyphenols have a hydrophobic internal core and numerous external hydroxyl groups.
By virtue of this structure, they react with proteins, specifically binding to hydrophobic
regions [37], but also establishing numerous hydrogen bonds, showing particularly high
affinity for Proline-rich proteins [38] such as collagen and elastin [39]. In addition, they
are efficient antibacterial agents and reduce inflammation and antigenicity [40]. Recently
we showed that peri-arterial delivery of PGG to rat abdominal aorta prevented aneurysm
formation or progression and did not elicit any detectable changes in serum liver enzyme
activities or liver histology, clearly showing that PGG was not toxic at local or systemic
levels [10]. Moreover, extractables obtained from PGG-fixed tissues exhibited very low
in vitro cytotoxicity towards fibroblasts and smooth muscle cells [41] and thus can be
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used safely in tissue engineering applications [42-46]. In current studies we have shown
that PGG binds strongly to pericardial collagen and this binding was stable for at least 3
weeks in vivo.

4.5

Conclusions
Decellularized pulmonary arteries can be prepared by our method to be used as

the spongiosa layer in our aortic heart valve constructs. Decellularized pericardium
fulfills many properties required for use in valvular tissue engineering, including
adequate mechanical properties, minimal cytotoxicity, excellent cell repopulation
potential and propensity for matrix remodeling. Such collagen scaffolds emerge superior
to polymer scaffolds in terms of mechanical and biological properties, but also maintain a
natural tendency to degenerate rapidly in vivo unless stabilized. Glut cross-linking fully
stabilizes collagen but does not allow for tissue remodeling and also induces calcification
when implanted subdermally in rats. Conversely, PGG is a mild, non-toxic, reversible
collagen stabilizing agent capable of controlling tissue degradation. PGG treated collagen
does not calcify in vivo and supports host cell infiltration and matrix remodeling. In
contrast, UV treatment induced exstensive changes in the mechanical properties and
induced profuse calcification of the fibrous collagen scaffold, therefore the use of UV
cross-linking was no investigated further as a fixation option. In conclusion, PGG
treatment is a promising collagen stabilization process for heart valve tissue engineering.
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CHAPTER 5
INVESTIGATION OF SCAFFOLD ADHERENCE METHODS FOR TRILAYERED TISSUE ENGINEERED HEART VALVES
(AIM 2)

5.1

Introduction
Native aortic valve leaflets are complex structures composed of external layers,

the fibrosa (composed of collagen) on the arterial aspect and the ventricularis (collagen
and elastin) on the ventricular aspect. The fibrous layers are sustained internally by a
highly hydrated central spongiosa layer (rich in proteoglycans) that serves as a cushion
material to mediate deformations of the fibrous layers, allows shearing between the outer
layers and absorbs compressive forces during valve function [1-3]. Lack of a buffering
layer results in large shear stress and tissue buckling when subjected to bending [4].
Tissue engineering, the science of combining scaffolds, cells and specific signals
to create living tissues is feasible and holds great promise for treatment of heart valve
disease [5]. Two main strategies have been developed in recent years. The first is based
on use of decellularized porcine valves followed by in vitro or in vivo repopulation with
cells of interest. Despite their excellent mechanics, acellular valves are very dense and
thus difficult to repopulate with desired cells. The second approach employs cell seeded
polymeric biodegradable matrices [6] or scaffolds built from fibrin [7]. While polymeric
and fibrin-based scaffolds shown very promising results, decellularized these degradable
matrices have insufficient strength to withstand arterial pressures immediately after
implantation.
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Our novel strategy relies on use of stabilized collagen scaffolds that mimic the
natural valve fibrous layers, based on decellularized porcine pericardium [8] and delicate,
highly hydrated porous collagen scaffolds to be used as the middle spongiosa layer.
Chemically stabilized pericardium has outstanding mechanical properties, a good record
of implantation in humans as valves, and as reconstructive surgery biomaterial patches in
other organs [9-15]. To reduce scaffold biodegradation, we have also investigated the use
of penta-galloyl glucose (PGG), a naturally derived collagen-binding polyphenol [8, 16].
No reports to date have documented the use of PGG-stabilized acellular pericardium for
construction of tissue engineered heart valves. Since the xenoantigen Gal1-3Gal (Gal),
is responsible for rejection of vascularized organ transplants we are paying special
attention to Gal detection in decellularized scaffolds [17-21].
Recognizing the outstanding mechanical performance of natural valve
homografts, the vital importance of the three leaflet layers [22], and the need for
reconstruction of the physiologic valve design, we developed five building blocks for this
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) trilayered constructs that mimic the native heart valve histo-architecture, d) autologous
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical
cues to induce stem cell differentiation into valvular cells capable of maintaining matrix
homeostasis.
To assemble the 3D heart valve structures we developed and implemented use of
biological adhesives in tissue engineering. At a minimum, these adhesives need to exhibit
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adequate bond strength and elasticity, long term stability and biocompatibility. In current
study we chose to implement a modified albumin/glutaraldehyde adhesive for the
construction of living heart valves. In Chapter 4 we reported on extensive
characterization of the acellular fibrous pericardial scaffolds and spongy pulmonary
artery used to mimic the fibrosa and ventricularis layers and spongiosa layers,
respectively [8]. In current study we describe the use of these novel scaffolds to be used
as the layers and utilization of a biological glue to assemble the tri-layered constructs.

5.2

Materials and Methods

5.2.1 Materials
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose,
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
(www.omnichem.be). Human bone marrow derived stem cells (hBMSCs) were obtained
from Cell Applications, Inc. San Diego, CA) and all other chemicals were of highest
purity available from Sigma Aldrich, St. Louis, MO.

5.2.2 Methods
5.2.2.1 Development and testing of the scaffold adhesive
Since bonding layers of collagen scaffolds is essential for our approach, we
developed a scaffold adhesive based on protein-aldehyde mixtures, inspired from the
FDA-approved BioGlue (CryoLife, Kennesaw, GA) developed as a haemostatic agent.
BioGlue is composed of 45% (w/v) bovine serum albumin and 10% glutaraldehyde
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solutions which are stored independently in a double-barreled syringe and dispensed
through a mixing tip to yield a quickly setting gel. Initial testing of the original
BioGlue on acellular pericardial scaffolds showed that setting time was too short and
once bonded, of insufficient mechanical strength for creation of engineered heart valves.
Thus we increased albumin concentration to 55% and decided to apply it in two steps,
first the protein layer and then glutaraldehyde using single-barreled syringes. This
approach ensured that the albumin solution first infiltrated several scaffold layers before
being fully crosslink by the aldehyde. The volumetric ratio of albumin to glutaraldehyde
was maintained at about 5 to 1. This higher protein concentration reduced the fluidity of
the solution and allowed for precise positioning of the gluing spots. The new adhesive
was coined “BTglue” and used in all studies shown below.

5.2.2.2 Lap shear
The test was performed according to ASTM 2255-05. Fibrous scaffolds were cut
into 2.5 x 7 cm strips, overlapped over a 1 cm wide area and bonded using the BTglue.
The specimens were subjected to increasing loads in the testing frame of a MTS Synergy
100 (Eden Prairie, MN) machine at a crosshead speed of 5 mm/min at room temperature
(Figure 5.1).
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Figure 5.1: Testing of the scaffold adhesive. To test bond strength samples were glued
by partial overlap subjected to pullout forces and shear strength calculated.

The apparent shear strength was calculated as the maximum load divided by the bonded
area and expressed as Pa.

5.2.2.3 Shear properties
Squares (20 x 20 mm) of fibrous scaffolds incorporating 10 x 10 mm of spongiosa
layer were glued together using BTglue as described above. The samples were mounted
onto a micromechanical testing device (Mach-1 Micromechanical Systems, Biosyntech,
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MN) and sheared horizontally to mimic physiologic movements of valve leaflets (Figure
5.2).

Figure 5.2: Testing of the scaffold adhesive. Shear properties of glued layers in
which spongiosa scaffolds (S) were glued between two fibrous scaffolds (F) using
BTglue (BG).

A deflection was applied by moving one of the shear plates with the linear positioner of
the Mach-1 (Figure 5.2 (B)). The shear angle was calculated by finding the arctangent of
the ratio of deflection over tissue thickness (Figure 5.2 (C)). Shear force was recorded by
the load cell and converted to shear stress by normalizing to the area of specimen. Shear
stress-shear angle relationships were compared to fresh valve cusps and 0.5%
glutaraldehyde-fixed valve cusps.

5.2.2.4 Cytotoxicity studies on BTglue
Fibrous scaffold samples (15 x 15 mm) were prepared and BTglue (200 l
albumin followed by 40 l glutaraldehyde) was applied on one surface of the scaffold.
Scaffolds were then divided into two groups; one group (n = 3) was treated with 50%
FBS/DMEM mixture for surface passivation (24 hours at 37 oC), rinsed and then treated
for 2 hours in 1% Glycine in PBS for complete aldehyde group neutralization.
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Figure 5.3: Testing BTglue cytotoxicity. Fibrous collagen scaffolds (CS) to which a
single layer of BTglue (BG) was applied were neutralized with FBS/glycine solutions (+)
or were used without neutralization (-) and were then seeded with fibroblasts.
The second group was treated with PBS for 26 hours at 37 oC as control. Rat dermal
fibroblasts (50 x 103 cells per sample) were seeded on the scaffolds, cultured in
DMEM/10% FBS media and MTS assay and Live/Dead performed 6 days after seeding.
Number of living cells was calculated from MTS absorbance values (A490) from a
calibration curve prepared with rat dermal fibroblasts cultured on standard culture plates.

5.2.2.5 Cytotoxicity studies on PGG-treated and glued fibrous scaffolds
Round fibrous scaffold coupons (3 cm2) were prepared and 120 l of BTglue (100
l albumin followed by 20 l glutaraldehyde) were applied on one surface and on only
one half of the scaffold, leaving half of scaffold surface untreated with glue. Scaffolds
were then treated with penta-galloyl-glucose (PGG) (0.1% and 0.15% PGG in 50 mM
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phosphate buffer, pH 5.5 containing 20% isopropanol, n = 3 scaffolds per group) for 24
hours at 22oC.

Figure 5.4: PGG toxicity testing. Fibrous collagen scaffolds (CS) to which a layer of
BTglue (BG) was applied on ½ of the surface, were treated with PGG (0.1% and
separately 0.15%), subjected to short wash and separately long wash procedures,
neutralized with FBS/glycine and then seeded with fibroblasts.

Scaffolds not treated with PGG served as controls. Samples were also treated with 0.2%
glutaraldehyde in PBS as positive cytotoxic controls. Scaffolds were then divided into
two groups; one group was rinsed in sterile PBS containing 0.02% sodium azide for 20
minutes at room temperature under gentle agitation (short wash); the second group was
rinsed in sterile PBS/azide for 5 days with daily changes at room temperature under
gentle agitation (long wash). Scaffolds were rinsed, treated with FBS and glycine for
neutralization (as above) and stored in sterile saline. Rat dermal fibroblasts (1x105 cells
per scaffolds) were seeded on the scaffolds, cultured and MTS and Live/Dead assays

127

performed 5 days after seeding. Results are expressed as percentage viability relative to
control samples (non-PGG treated group).

5.2.2.6 Tri-layered scaffolds; stability and mechanical properties
To test whether tri-layered scaffolds maintain stabilization properties, a layer of
porous spongiosa scaffold was entrapped between two fibrous scaffold layers using
BTglue as described above. The constructs were then subjected to 0.1% PGG for 24
hours, long wash protocol, neutralization as above and then exposed to collagenase (6.25
units/ml, 100 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3, pH=7.8) for up to 20 days at
37ºC and resistance to enzyme measured by gravimetry.

5.2.2.7 Shear properties
To assess shear behavior of engineered tri-layered leaflets, 20 x 20 mm squares of
fibrous scaffolds incorporating 10 x 10 mm of spongiosa layer were glued together using
BTglue as described above. The two surfaces of glued engineered leaflets were mounted
onto custom made plates using cyanoacrylate glue and mounted onto a micromechanical
testing device (Mach-1 Micromechanical Systems, Biosyntech, MN) and sheared to
mimic physiologic movements of valve leaflets. A deflection was applied by moving one
of the shear plates with the linear positioner of the Mach-1. The shear angle was
calculated by finding the arctangent of the ratio of deflection over tissue thickness. Shear
force was recorded by the load cell and converted to shear stress by normalizing to the
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area of specimen. Shear stress-shear angle relationships of tissues were then obtained and
properties were compared to fresh valve cusps and glutaraldehyde-fixed valve cusps.

5.2.2.8 In vivo evaluation of glued scaffolds
Tri-layered constructs were prepared by gluing one 10 x 10 mm spongiosa
scaffold between two fibrous layers cut between 10-15 x 10-15 mm using a 1-2 mm wide
line of glue around the four sides. Samples were treated with 0.1% PGG, long wash
procedure and neutralization and implanted subdermally (two implants per rat) in male
juvenile Sprague-Dawley rats (n = 10) as described before [8]. High density polyethylene
(HDPE) samples were also implanted as negative controls as per ISO-10993 standards (n
= 3 rats) and sutured fibrous scaffolds served as controls.

Figure 5.5: Scaffolds for implantation. (A) is a representative scaffold implanted
showing the spongy scaffold between two layers of fibrous scaffold (spongy scaffold
visualized due to the translucency of the fibrous scaffold. (B) shows the sutured scaffold
that was implanted as a control.
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The animal protocol was approved by the Animal Research Committee at
Clemson University and NIH guidelines for the care and use of laboratory animals (NIH
publication #86-23 Rev. 1996) were observed throughout the experiment. The rats were
humanely euthanized at 5 weeks after surgery and samples retrieved for histology,
calcium assay and matrix metalloproteinase (MMP) analysis [8]. To test for remote organ
toxicity, liver, heart and kidney samples were collected from each animal.
For histology, paraffin sections were stained with Hematoxylin and Eosin,
Masson’s Trichrome and Alizarin Red stains. For identification of infiltrating cell types,
immunohistochemistry was performed as described before [8] using mouse anti-rat
monoclonal antibodies to macrophages (1:200 dilution, Chemicon, Temecula, CA),
vimentin (1:500 dilution, Sigma, St. Louis, MO), type III collagen (1:200 dilution,
Sigma, St. Louis, MO) and fibronectin (1:100 BD Labs) and sections were lightly
counter-stained with Hematoxylin. As positive controls we used same antibodies to stain
normal rat spleen (macrophage control) and rat skin (fibroblast control) in parallel with
the explant sections.

Statistics
Results are represented as means ± the standard error of the mean (SEM). Statistical
analysis was performed with one way Analysis of Variances (ANOVA) and results were
considered significantly different at p < 0.05.
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5.3

Results

5.3.1 Scaffold adhesive
Our novel scaffold adhesive (BTglue) showed good bonding strength when
compared to other available medical grade glues (Figure 5.6) . BT-glue was five-fold
stronger than fibrin glue and 20-plus stronger than silicon glue. When compared to
Dermabond, a cyanoacrylate-based glue, BTglue was weaker; however, cyanoacrylates
are not FDA-approved for internal use (Figure 5.6). Mechanical analysis revealed that
the glued tri-layered leaflets were found to be stiffer than native porcine aortic leaflets but
not different from glutaraldehyde-fixed porcine leaflets, and allowed shearing to lower
angles (Figure 5.7).

Figure 5.6: Testing of the scaffold adhesive. To test bond strength samples were glued by
partial overlap subjected to pullout forces and shear strength calculated. Values are
also shown for cyanoacrylate glue and fibrin glue.
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Figure 5.7. Testing of the scaffold adhesive. Test results showing shear stress-shear
angle curves of the tri-layered construct; groups A and B are replicate experiments.
Native porcine aortic valve leaflets and glutaraldehyde-fixed (Glut) leaflets were also
plotted as a comparison (data provided by Jun Liao, University of Mississippi).

Additionally, trichrome evaluation of the samples prepared for lap shear showed glue
infiltration into and between the collagen fibers of the fibrous scaffolds.
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Figure 5.8: Testing of the scaffold adhesive. To test bond strength samples were glued
by partial overlap subjected to pullout forces. Trichrome evaluation of these samples
showed signification infiltration of the BTglue into the scaffolds and association with the
collagen fibers.

BTglue was quite cytotoxic when left untreated, but was rendered very cell friendly and
supported fibroblast proliferation after treatment with FBS and glycine to neutralize
residual glutaraldehyde residues (Figures 5.9, 5.10, 5.11).
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Figure 5.9: Cytotoxicity studies (A) Phase contrast image showing living cells. (B) Dead
cells in glutaraldehyde-treated positive control sample. Bars are 100 µm.

Figure 5.10: Cytotoxicity studies (A) Live cells covering both the glue and the scaffold
surfaces. (B) Live cells covering the glue surface. Bars are 100 µm.
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Figure 5.11: Testing BTglue cytotoxicity. Fibrous collagen scaffolds (CS) to which a
single layer of BTglue (BG) was applied were neutralized with FBS/glycine solutions (+)
or were used without neutralization (-) and were then seeded with fibroblasts.
Cells numbers were measured at time zero and after 6 days using the MTS assay.
*denotes statistical significance.

The glued pericardial constructs showed moderate resistance to collagenase (13%, 19%
and 23% mass loss after 7, 14 and 20 days, respectively) possibly due to
glutaraldehyde cross-linking of scaffold collagen in the gluing areas.
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5.3.2 PGG cytotoxicity
To test toxicity of PGG-treated and glued samples, glued scaffolds were treated
with increasing concentrations of PGG, rinsed shortly or for several days (long wash) and
seeded with fibroblasts . MTS and Live/Dead results showed that long wash significantly
improved cell viability as compared to the short wash protocol (p < 0.05) (Figure 9,10,
12).

Figure 5.12: PGG toxicity testing. Fibrous collagen scaffolds (CS) to which a layer of
BTglue (BG) was applied on ½ of the surface, were treated with PGG (0.1% and
separately 0.15%), subjected to short wash and separately long wash procedures,
neutralized with FBS/glycine and then seeded with fibroblasts. Cell numbers were
measured after 5 days using the MTS assay. All values were statistically different
(p<0.05).

Enzyme tests showed that neither treatments changed resistance to collagenase (data not
shown), indicating that neutralization is not deleterious to scaffold stabilization.
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5.3.3 In vivo studies
To evaluate biocompatibility of our tri-layered constructs we implanted samples
subdermally in juvenile rats and analyzed them after 5 weeks. Animals exhibited similar
weight gain (p < 0.05) indicating lack of systemic toxicity for all implants. In addition,
histological analysis of liver, heart and kidney samples indicated lack of remote organ
toxicity for all implants (data not shown). Implants were surrounded by a thin capsule
and showed good integration into host subdermal tissues. As expected, negative control
HDPE implants induced minimal host reactions which were limited to a very thin
capsule.
Histological analysis of implanted tri-layered scaffolds revealed that scaffolds
maintained their integrity and the glued areas did not separate or delaminate. The
spongiosa scaffolds were found intact and no host cells were present inside the glued
scaffold “pockets”, indicating that the seal provided by the BTglue was not compromised.
Host cells were present around the implants but not within the thickness of the acellular
pericardium. Cells mostly associated with external collagen fibers which exhibited a
“frayed” or unraveled aspect indicative of possible collagen degeneration (Figure 5.13).
In many areas degraded collagen fibers were replaced by new matrix, as detected by
Trichrome staining (Figure 5.14).
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Figure 5.13. Implantation results. PGG-treated fibrous collagen scaffolds (CS)
containing spongiosa scaffolds (SP) glued with BTglue (BG) were implanted
subdermally and analyzed by histology after 5 weeks. (A-C) H&E stain of (A)
unimplanted, and (B, C) implanted scaffolds.

Figure 5.14. Implantation results. PGG-treated fibrous collagen scaffolds (CS)
containing spongiosa scaffolds (SP) glued with BTglue (BG) were implanted
subdermally and analyzed by histology after 5 weeks. Trichrome stain (collagen blue,
cells dark pink) of (D) unimplanted, and (E, F) implanted scaffolds.

Matrix metalloproteinase (MMP) activity was measured in explants from both
groups using gelatin zymography (not shown); one major protease was identified in tissue
extracts, namely MMP-2, migrating at around 65-80 kDa. These observations suggest
that PGG-treated collagen scaffolds are not cytotoxic, are slowly degradable in vivo and
may possibly support matrix remodeling. Immunohistochemistry revealed that the
infiltrating cells were mainly macrophages and fibroblasts (Figure 5.15).
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Figure 5.15: Implantation results: Immunohistochemical staining for (A,B and insert)
macrophages, (C,D and insert) vimentin, (E,F and insert) collagen type III, fibronectin,
(G,H and insert) showing positive results. (A,B,D,F H = 20X magnification)(C,E,G = 10x
magnification)
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Chemical analysis revealed a very low tendency towards calcification of our trilayered glued constructs (5 ± 2 g Ca/mg dry). Alizarin Red S staining confirmed these
data and revealed calcium deposits in only 1 sample out of 6 analyzed (Figure 5.16).
Calcium deposits appeared to associate with the glue and with the PGG-treated collagen
scaffold in the vicinity of the BTglue suggesting that traces of glutaraldehyde may induce
calcium deposition. Overall these observations support earlier data which showed that
despite effective stabilization, PGG treatment does not induce collagen calcification [8].

Figure 5.16: Implantation results. PGG-treated fibrous collagen scaffolds (CS)
containing spongiosa scaffolds (SP) glued with BTglue (BG) were implanted
subdermally and analyzed by histology after 5 weeks. Alizarin red stain for calcium
deposits in the only sample (out of 6) which showed signs of calcification.

5.4

Discussion
For heart valve assembly, gluing techniques were developed and tested in vitro

and in vivo. To our knowledge this is a first report on scaffold gluing techniques for heart
valves tissue engineering. The albumin/glutaraldehyde glue has evolved conceptually
from the very popular gelatin-resorcinol-formaldehyde (GRF), still in use throughout
Europe and the USA [23]. Histology showed that application of the BTglue in two steps
allowed albumin to first infiltrate several layers of collagen fibers within the scaffold
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surfaces before application of the glutaraldehyde component. The bond strength of
BTglue was found to be adequate for our applications and during shearing tests,
bioreactor studies and subdermal implantation, the glue maintained its integrity, stability
and an ability to seal. These tests, while elucidating the importance of a spongiosa layer
and validating the effectiveness of the Bioglue, showed that adhering two pieces of
pericardium together allowed for some shearing, revealing that the shear properties
within our tissue engineered construct will rely heavily on the pulmonary artery scaffold,
necessitating a tri-layered assembly. This is further substantiated by the fact that our test
samples were adhered together at all edges completely by BTglue, with little spongiosa
represented by the pulmonary artery scaffold. The BTglue in the shear stress-shear strain
experiment represents the case by which all shearing is dependent on the amount of
BTglue used, not the spongiosa. This scenario is a worst-case scenario, by which the glue
makes the entire construct more stiff and influences the shear properties. This further
highlights the need to perfect the glue-adherence points and amounts whereby the amount
of glue and position of gluing will not have a deleterious effect on stiffness and ability of
the layers to shear.
Scaffolds adhered with BTglue exhibited resistance to proteases and were easily
rendered cytocompatible by neutralization. There is a possibility that the presence of glue
between the spongiosa and fibrosa/ventricularis layers will inhibit homogeneous
mesenchymal stem cell distribution in all three layers. To address this issue, we must
optimize the assembly process to determine precise positioning of the gluing “points” and
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the minimal amount of glue required to maintain integrity while allowing for cell
migration within all three layers.
Upon sub-dermal implantation of the glued construct we observed one single area
of calcification in close apposition with the glue, indicating that enhanced neutralization
of aldehyde groups would be needed in the future. We have shown earlier that simple
amines and diamines are capable of neutralizing effects of glutaraldehyde [24]. Perfecting
the gluing application will also possibly alleviate this potential effect. The Glut-mediated
calcification is further supported by the lack of cellular infiltration into the spongiosa
layer. Lack of cellular infiltration can prove advantageous in future studies in which cellseeded pulmonary artery scaffolds are inserted into the construct. The scaffold can thus
serve as a immune privileged site, by which any type of cell can be seeded onto the
scaffold.
In current study we used PGG as a stabilizer for the fibrous collagen scaffolds.
The most effective method to create heart valve-shaped constructs from decellularized
pericardium was treating dry scaffolds with PGG. In vitro studies showed that PGG,
when used in concentrations higher than 0.15% could be cytotoxic [25]. To achieve an
optimum balance of cell viability and scaffold stability, we chose to use 0.1% PGG
followed by rinsing and neutralization. PGG treatment of the BTglue was not detrimental
to gluing properties, confirming earlier studies which showed that use of glutaraldehyde
in conjunction with PGG had a synergistic effect on tissue stabilization [26]. In vivo
studies also showed that although most of the fibrous collagen scaffold was intact after 5
weeks implantation, there was some unraveling of the collagen fibers on the outside
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edges of the implants associated with infiltration of macrophages, fibroblasts and signs of
remodeling.

5.5

Conclusions
This study is a stepping stone towards development of a novel approach to heart

valve tissue engineering. Recognizing the importance of each of the three layers in a
native aortic heart valve, we have taken one step towards this goal by utilizing a
bioadhesive that may hold the layers together. The BTglue was found to possess the
mechanical properties necessary to maintain adhesion of the layers together while at the
same time allowing cellular survival and growth on our glued scaffolds. This technique of
adhering different scaffolds together to form a single tri-layered construct thus holds
promise for applications in heart valve tissue engineering.

5.6

References

1.

Talman, E.A. and D.R. Boughner, Glutaraldehyde fixation alters the internal
shear properties of porcine aortic heart valve tissue. Ann Thorac Surg, 1995.
60(2 Suppl): p. S369-73.

2.

Talman, E.A. and D.R. Boughner, Internal shear properties of fresh porcine
aortic valve cusps: implications for normal valve function. J Heart Valve Dis,
1996. 5(2): p. 152-9.

3.

Schoen, F.J. and R.J. Levy, Tissue heart valves: current challenges and future
research perspectives. J Biomed Mater Res, 1999. 47(4): p. 439-65.

4.

Vesely, I., D. Boughner, and T. Song, Tissue buckling as a mechanism of
bioprosthetic valve failure. Ann Thorac Surg, 1988. 46(3): p. 302-8.

5.

Yacoub, M., Viewpoint: Heart valve engineering. Interview by James Butcher.
Circulation, 2007. 116(8): p. f44-6.

143

6.

Sutherland, F.W., et al., From stem cells to viable autologous semilunar heart
valve. Circulation, 2005. 111(21): p. 2783-91.

7.

Robinson, P.S., et al., Functional tissue-engineered valves from cell-remodeled
fibrin with commissural alignment of cell-produced collagen. Tissue Eng Part A,
2008. 14(1): p. 83-95.

8.

Tedder, M.E., et al., Stabilized collagen scaffolds for heart valve tissue
engineering. Tissue Eng Part A, 2009. 15(6): p. 1257-68.

9.

Liao, J., et al., Molecular orientation of collagen in intact planar connective
tissues under biaxial stretch. Acta Biomater, 2005. 1(1): p. 45-54.

10.

Obermiller, J.F., et al., A comparison of suture retention strengths for three
biomaterials. Med Sci Monit, 2004. 10(1): p. PI1-5.
Oswal, D., et al., Biomechanical characterization of decellularized and crosslinked bovine pericardium. J Heart Valve Dis, 2007. 16(2): p. 165-74.

11.

12.

Simionescu, D., A. Simionescu, and R. Deac, Mapping of glutaraldehyde-treated
bovine pericardium and tissue selection for bioprosthetic heart valves. J Biomed
Mater Res, 1993. 27(6): p. 697-704.

13.

Simionescu, D., R.V. Iozzo, and N.A. Kefalides, Bovine pericardial
proteoglycan: biochemical, immunochemical and ultrastructural studies. Matrix,
1989. 9(4): p. 301-10.

14.

Simionescu, D.T. and N.A. Kefalides, The biosynthesis of proteoglycans and
interstitial collagens by bovine pericardial fibroblasts. Exp Cell Res, 1991.
195(1): p. 171-6.

15.

Deac, R.F., D. Simionescu, and D. Deac, New evolution in mitral physiology and
surgery: mitral stentless pericardial valve. Ann Thorac Surg, 1995. 60(2 Suppl):
p. S433-8.

16.

Isenburg, J.C., et al., Structural requirements for stabilization of vascular elastin
by polyphenolic tannins. Biomaterials, 2006. 27(19): p. 3645-51.

17.

Azimzadeh, A., et al., Comparative study of target antigens for primate
xenoreactive natural antibodies in pig and rat endothelial cells. Transplantation,
1997. 64(8): p. 1166-74.

144

18.

Strokan, V., et al., Heterogeneous expression of Gal alpha1-3Gal xenoantigen in
pig kidney: a lectin and immunogold electron microscopic study. Transplantation,
1998. 66(11): p. 1495-503.

19.

Daly, K.A., et al., Effect of the alphaGal epitope on the response to small
intestinal submucosa extracellular matrix in a nonhuman primate model. Tissue
Eng Part A, 2009. 15(12): p. 3877-88.

20.

McPherson, T.B., et al., Galalpha(1,3)Gal epitope in porcine small intestinal
submucosa. Tissue Eng, 2000. 6(3): p. 233-9.

21.

Raeder, R.H., et al., Natural anti-galactose alpha1,3 galactose antibodies delay,
but do not prevent the acceptance of extracellular matrix xenografts. Transpl
Immunol, 2002. 10(1): p. 15-24.

22.

Schoen, F.J., Cardiac valves and valvular pathology - Update on function,
disease, repair, and replacement. Cardiovascular Pathology, 2005. 14(4): p. 189194.

23.

Chao, H.H. and D.F. Torchiana, BioGlue: albumin/glutaraldehyde sealant in
cardiac surgery. J Card Surg, 2003. 18(6): p. 500-3.

24.

Simionescu, A., D. Simionescu, and R. Deac, Lysine-enhanced glutaraldehyde
crosslinking of collagenous biomaterials. J Biomed Mater Res, 1991. 25(12): p.
1495-505.

25.

Isenburg, J.C., et al., Elastin stabilization for treatment of abdominal aortic
aneurysms. Circulation, 2007. 115(13): p. 1729-37.

26.

Isenburg, J.C., D.T. Simionescu, and N.R. Vyavahare, Tannic acid treatment
enhances biostability and reduces calcification of glutaraldehyde fixed aortic
wall. Biomaterials, 2005. 26(11): p. 1237-45.

145

CHAPTER 6
MOLDING, ASSEMBLY, AND BIOREACTOR TESTING OF TRI-LAYERED
TISSUE ENGINEERED HEART VALVES
(AIM 3)

6.1

Introduction
Our novel strategy relies on use of stabilized collagen scaffolds that mimic the

natural valve fibrous layers, based on decellularized porcine pericardium [8] and delicate,
highly hydrated porous collagen scaffolds to be used as the middle spongiosa layer.
Chemically stabilized pericardium has outstanding mechanical properties, a good record
of implantation in humans as valves, and as reconstructive surgery biomaterial patches in
other organs [9-15]. To reduce scaffold biodegradation, we have also investigated the use
of penta-galloyl glucose (PGG), a naturally derived collagen-binding polyphenol [8, 16].
No reports to date have documented the use of PGG-stabilized acellular pericardium for
construction of tissue engineered heart valves. Since the xenoantigen Gal1-3Gal (Gal),
is responsible for rejection of vascularized organ transplants we are paying special
attention to Gal detection in decellularized scaffolds [17-21].
Recognizing the outstanding mechanical performance of natural valve
homografts, the vital importance of the three leaflet layers [22], and the need for
reconstruction of the physiologic valve design, we developed five building blocks for this
new approach: a) partially stabilized collagenous scaffolds which degrade slowly with
time, b) anatomically analogous 3-D heart valve shapes made from solid molds, c) trilayered constructs that mimic the native heart valve histo-architecture, d) autologous
multipotent mesenchymal stem cells for repopulation and remodeling and e) mechanical
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cues to induce stem cell differentiation into valvular cells capable of maintaining matrix
homeostasis.
In current study we describe development of molds to be used as the forms on
which to layer the 2 scaffolds we have developed and the utilization of our biological
BTglue to assemble the tri-layered constructs.

6.2

Materials/Methods

6.2.1 Materials
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose,
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
(www.omnichem.be). Silicone was obtained from Copy Flex Liquid Silicone, Cincinnati,
OH (www.makeyourownmolds.com).

6.2.2 Methods
6.2.2.1 Construction of molds for anatomically correct valves
Whole porcine hearts collected at a local abattoir were brought to the lab on ice,
rinsed with saline, and aortic and pulmonary valves dissected together with preservation
of the entire anatomy of the cardiac base. Valves were then fixed for 48 hours in 0.6%
glutaraldehyde (Glut) in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
buffered saline (pH=7.4) at 22ºC. At the onset of fixation the aortic heart valve cusps
were lightly stuffed with Glut-imbibed cotton balls to maintain the valve in closed
position. After removal of the cotton balls and rinsing, liquid Silicone (Copy Flex Liquid
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Silicone, Cincinnati, OH) was poured into the aortic valve via the ascending aorta, while
the coronaries were plugged to prevent leakage with pegs made from the silicone, and the
silicone allowed to harden for 24 hours at room temperature. Final molds could easily be
removed from the aorta.
After removal of the mold, a negative mold was formed in which the collagen
scaffold could be pressed between to form the shape of the aortic valve. Briefly, the
initial mold was coated with a silicone grease, to allow for easy removal) and placed into
a specimen cup filled with approximately 80 mls of silicone. The silicone was allowed to
harden for 24 hours at room temperature. Finally, the mold was easily extracted from the
specimen cup leaving an exact negative mold of the molded aortic valve in the specimen
cup. The specimen cup was then cut away from the negative mold.

6.2.2.2 Construction of single layer, anatomically correct valves
Fibrous collagen scaffolds prepared from porcine pericardium (see Chapter 4)
were placed onto the molds, with the fibrous side of the pericardium in direct contact to
the mold, and then the mold s pressed into the negative mold to ensure complete shaping
of the collagen scaffold. After removal of the mold from the counter mold, the collagen
scaffold was adhered to the counter mold with pins in the central gap, along the edges of
the cusp, and along the base of the valve and air dried for 48 hours in a sterile bio-hood.
The dried scaffold was then removed and fixed with 0.3% PGG for 24 hours. After
fixation, the individual leaflets were separated by incisions to result in the 3 distinct
leaflets. To test functionality of the heart valve-shaped fibrous scaffolds they were
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mounted onto a silicone mock aorta support in a home-made pulse duplicator heart valve
bioreactor tester system (described in detail in manuscript by Leslie Sierad et. al.
accepted to Cardiovascular Engineering and Technology, May 2010). and cycled at about
1 Hz. Still frames were captured from digital movies using video editing software
(VideoStudio 9, ULead Systems Inc., Torrance, CA).

6.2.2.3 Construction of tri-layered, tissue engineered valves
To test the association of the 3 layers and create layered constructs that resemble
the valve histo-architecture, two

sheets

of

fibrous pericardial

scaffolds

were

superimposed and a small sheet of spongy scaffold was entrapped between the two
fibrous

scaffolds.

The

edges

were

then

sealed

by

staples.

To create the histologically and anatomically correct scaffold constructs, molds
formed above were used for the following purposes. Two fibrous collagen scaffolds
prepared from porcine pericardium (described above) were placed onto negative molds
(with fibrous sides placed together) and air dried for 48 hours in a sterile bio-hood. The
scaffold was then separated and dissected at the level of the cusps. The two identical
valve-shaped scaffolds were overlapped (with fibrous sides placed together again) and
assembled by applying BTglue to the entire scaffold surface corresponding to the aorta
and the sinuses, leaving the cusps un-attached.

For bioreactor testing, the original

porcine aortic root (from which the mold was cast) was rinsed in saline, the three native
valve cusps excised by dissection and the assembled engineered valve was secured inside
the aortic root using sutures and BTglue. To test functionality of the constructs they were
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mounted onto our heart valve bioreactor. The device consists of a valve mounting ring
assembly encased between a ventricular chamber and an aortic chamber filled with cell
culture medium. The medium is pushed through the valve by a flexible silicone
membrane diaphragm connected to an air pump. Extensive testing has shown that the
bioreactor ensures comparable pumping functions to a living heart (data not shown-see A
Pulsatile Bioreactor for Conditioning Tissue Engineered Heart Valves, MS Thesis by
Leslie Sierad, Clemson University, May 2009). The tissue engineered valve was
subjected to open-close cycles at 60 beats per minute, 40/20 mmHg, 10 mL stroke
volume, at 37 0C, 5% CO2 for 8 days. Cusp movements and still frames were captured
with a Logitech webcam.

6.3

Results

6.3.1

Construction of molds for anatomically correct valves
The long term aim of our studies is to create anatomically correct scaffolds to be

used as off-the-shelf constructs for heart valve tissue engineering. To create structures
that mimic the heart valve anatomy, we used silicon molds from porcine heart valves.
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Figure 6.1: Construction of molds for anatomically correct valves. Silicone molds were
prepared from porcine heart valves.

Figure 6.2: Construction of molds for anatomically correct valves. Silicone molds were
prepared from porcine heart valves seen in Figure 6.1. RC – right coronary; LC – left
coronary; a, b, c – the three leaflets.

The negative molds were then formed from the direct molds of the porcine aortic valves.
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Figure 6.3: Construction of molds for anatomically correct valves. Silicone molds were
prepared from porcine heart valves seen in Figure 6.1 and negative molds were formed
from the direct aortic valve molding.

6.3.2 Construction of single layer, anatomically correct valves
Scaffolds dried onto such molds adopted the valve structure down to very fine details
(Figure 6.4). This shape was maintained after rehydration and PGG stabilization. The
scaffold obtained a yellowish tint upon PGG fixation (Figure 6.5). The single-layer valve
was then mounted in our custom made bioreactor (Figure 6.6, 6.7) and functioned
acceptably in a pulse duplicator system (Figure 6.8).
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Figure 6.4: Construction of Single Layer, anatomically correct valves. Wet fibrous
scaffolds (A) were dried onto molds. Upon removal, they retained the shape of the aortic
valve, with the fine finistrations of the mold (B and C).
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Figure 6.5: Construction of Single Layer, anatomically correct valves. Rehydrated/PGG
fixed scaffold with the 3 leaflets dissected (C). (A) shows the ventricular side, while (B)
shows the aortic side of the valve. RC – right coronary; LC – left coronary; a, b, c – the
three leaflets.

Figure 6.6: Picture and computer aided drafting representation of assembled bioreactor.
(adapted from Leslie Sierad)
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Figure 6.7: Cross-sectional view of the bioreactor demonstrating the pumping actions
during systole and diastole. Black arrow signifies where the tissue engineered valve is
mounted (Courtesy of Lee Sierad).

Figure 6.8: Still frames acquired from digital movies of a valve-shaped fibrous scaffold
tested for functionality. The three leaflets are labeled A, B, and C.
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6.3.3

Construction of tri-layered, tissue engineered valves
The long term aim of our studies is to build not only anatomically correct

scaffolds but these scaffolds must be histologically correct structures for heart valves. To
this end we have used different collagen scaffolds to form the 3 layers of the native aortic
valve.
Histological analysis showed a unique tri-layered of the tri-layered structure
resembling the heart valve histo-architecture (Figure 6.9) where a spongiosa layer
(S) is entrapped between two fibrous layers (F).

Figure 6.9: Tri-layered scaffolds made by entrapping a sheet of spongy (S) scaffold
between two fibrous (F) scaffolds and edges sealed by staples (A). Histology
and H&E stain (2.5 x) showed a fair resemblance to natural heart valve structure
(B).

Thickness of fibrous scaffold is 0.125 +/- 0.005 mm (mean

+/-

SEM

for n=40),

and thus the total thickness of tri-layered scaffolds is expected to be less than 0.5
mm (3 x 0.124).
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For making anatomically correct tri-layered constructs, after drying the two
fibrous scaffolds on their molds, the scaffolds have acquired the shape of the aortic valve
including the very delicate details of the 3D corrugations, which could then be preserved
permanently by stabilization with PGG (see Figure 6.4 and 6.5). Two identical valveshaped scaffolds were then overlapped and assembled using BTglue (Figure 6.10).
The entire construct was then sutured into the aortic root from which the silicone mold
shape was originally acquired. The reconstructed valve fit flawlessly within the natural
root (Figure 6.10 and 6.11).
Functionality testing of the heart valve-shaped scaffolds showed good leaflet
coaptation upon closure and adequate opening characteristics (Figure 6.11).
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Figure 6.10: Valve-shape constructs were assembled by overlapping two identical
fibrous scaffolds (A and B) and inserting a piece of spongy scaffold between the two
layers (E, arrow shows spongy scaffold). BTglue was used at the open edges of the cusps
(arrow in C) and both BTglue and sutures were placed at the level of valve wall, sinuses
and cusp insertion points (D).
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Figure 6.11: Tri-layered tissue engineered heart valve sutured inside a porcine aortic
root. (A,C) are top view and (B,D) are bottom view.
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Figure 6.12: Bioreactor testing of the tissue engineered heart valve (A,C) showing
comparable function to a living porcine aortic heart valve (B,D).
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6.4

Discussion
The long term aim of our studies is to create anatomically correct scaffolds to be

used as off-the-shelf constructs for heart valve tissue engineering. For this purpose we
created silicone molds from porcine aortic heart valves and then modeled decellularized
porcine pericardium into anatomically correct scaffolds. After drying them in their molds,
the scaffolds have acquired the shape of the aortic valve including the very delicate
details of the 3D corrugations, which could then be preserved by exposure to PGG. Two
identical valve-shaped scaffolds were then overlapped and assembled using BTglue and
sutured into the aortic root from which the silicone mold shape was originally acquired,
to mimic a potential clinical scenario. Functionality testing of the heart valve-shaped
scaffolds showed good leaflet coaptation upon closure and good opening characteristics .
However, there is a possibility that the presence of glue between the spongiosa and
fibrosa/ventricularis layers will inhibit homogeneous mesenchymal stem cell distribution
in all three layers. To address this issue, we are currently optimizing the assembly process
to determine precise positioning of the gluing “points” and the minimal amount of glue
required to maintain integrity while allowing for cell migration within all three layers.
In an envisioned clinical scenario (see Project Rationale for complete details),
imaging data obtained from the patient’s valve would be translated into solid molds using
a stereolithography system and the solid molds used for valve construction. Our current
approach of using solid molds formed by pouring liquid silicone into an intact valve will
obviously not be useful in a clinical setting, but our proof of concept work with the solid
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molds demonstrates that our scaffolds can be fashioned into anatomically and
histologically valve constructs comparable to the native aortic valve.

6.5

Conclusions
This study is a stepping stone towards development of a novel approach to heart

valve tissue engineering. We utilized two types of acellular collagen scaffolds, a flat
collagen sheet of high tensile strength and malleability and a highly hydrated scaffold
that mimics valvular spongiosa layer. The scaffolds were assembled into anatomically
analogous 3-D heart valve shapes using novel protein-based glue and tested in our
custom-made bioreactor for functionality. While many aspects and details need to be
optimized as far as scaffold assembly and animal testing are concerned, this approach
appears promising for our envisioned translational scenario.

6.6
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CHAPTER 7
STEM CELL DIFFERENTIATION WITHIN TRI-LAYERED TISSUE
ENGINEERED HEART VALVES
(AIM 4)

7.1

Introduction
The predominant cell populations in heart valves, valvular interstitial cells (VICs),

continuously secrete matrix components such as collagen, GAGs and as well as matrix
degrading enzymes such as matrix metalloproteinases (MMPs) and other matrix
degrading enzymes such as GAG-degrading enzymes that mediate remodeling that
mediate remodeling [1-3]. VICs exhibit a dynamic phenotypic spectrum ranging from
quiescent fibroblast-like cells (characterized by expression of vimentin, fibroblast surface
antigen and low expression of alpha-smooth muscle cell actin and MMP-13), to activated
VICs, assimilated as myofibroblasts (characterized by proliferation, migration and high
expression of alpha-smooth muscle cell actin) [4-8]. Overall, permanent interactions
between mechanical forces, valvular cells and the matrix dictate adaptability and
durability of heart valves. Duplication of these structures and interactions in a manmade device is truly the bioengineers’ dream and has the potential to provide tremendous
clinical benefits.
Cell sourcing for seeding heart valve scaffolds includes differentiated cells
(smooth muscle cells, fibroblasts) and mesenchymal or embryonic stem cells [9, 10].
Other cell sources include peripheral blood and human umbilical cord blood [11]. Upon
biochemical and/or mechanical stimulation, most of these cells express markers of
quiescent VICs such as vimentin, among others [12].
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As stated before, our approach aims to combine partially stabilized collagen
scaffolds that can be formed into anatomically analogous tri-layered, 3-D heart valve
shapes made from solid molds that mimic the native heart valve histo-architecture. Also,
we aim to use autologous multipotent mesenchymal stem cells for repopulation and
remodeling and mechanical cues to induce stem cell differentiation into valvular-like
cells capable of maintaining matrix homeostasis. To assemble the 3D heart valve
structures we developed and implemented use of biological adhesives in tissue
engineering, as discussed in Chapter 5. We have reported on extensive characterization of
the acellular fibrous pericardial scaffolds used to mimic the fibrosa and ventricularis
layers [13]. In current study we describe the use of our novel scaffolds to be used as the
spongiosa layer that can be seeded with adult stem cells. We also show that bioreactor
conditioning of stem cell-seeded tri-layered valves induced differentiation into VIC-like
cells.

7.2

Materials and Methods

7.2.1 Materials
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl-glucose,
PGG) was a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium
(www.omnichem.be). Human bone marrow derived stem cells (hBMSCs) were obtained
from Cell Applications, Inc. San Diego, CA) and all other chemicals were of highest
purity available from Sigma Aldrich, St. Louis, MO.
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7.2.2

Methods

7.2.2.1 Cell seeding of spongy scaffolds
Sterile spongiosa scaffolds were seeded with 5 x 104 cells/cm2 human bone
marrow derived stem cells (hBMSCs) by direct drop wise pipetting of cell suspensions
onto scaffolds and culturing for 2 days before being inserted into the fibrous scaffold
construct (described fully in Chapter 6). Briefly, two identical valve-shaped scaffolds
were overlapped and assembled by applying BTglue to the entire scaffold surface
corresponding to the aorta and the sinuses, leaving the cusps un-attached. For bioreactor
testing, the original porcine aortic root (from which the mold was cast) was rinsed in
saline, the three native valve cusps excised by dissection and the assembled engineered
valve was secured inside the aortic root using sutures and BTglue. The entire construct
was then rinsed and neutralized with 50% FBS and glycine (as described in Chapter 6).
To finalize assembly, stem cell-seeded spongiosa (see below) was inserted between the
two cusp-shaped scaffolds and the free cusp edges sealed with a thin line of BTglue. The
edges of the cusps were rapidly neutralized by dipping in glycine.

7.2.2.2 Cell seeded tri-layered construct bioreactor conditioning
To test functionality of the constructs they were mounted onto our heart valve
bioreactor (described in detail in manuscript accepted to Cardiovascular Engineering and
Technology, May 2010). The device consists of a valve mounting ring assembly encased
between a ventricular chamber and an aortic chamber filled with cell culture medium.
The medium is pushed through the valve by a flexible silicone membrane diaphragm
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connected to an air pump. Extensive testing has shown that the bioreactor ensures
comparable pumping functions to a living heart (data not shown-see A Pulsatile
Bioreactor for Conditioning Tissue Engineered Heart Valves, Thesis by Leslie Sierad,
May 2009). The stem cell-seeded tissue engineered valve was subjected to open-close
cycles at 60 beats per minute, 40/20 mmHg, 10 mL stroke volume, at 37 0C, 5% CO2 for
8 days. Cell viability after 8 days of bioreactor conditioning was performed by Live/Dead
stain. Cells were also stained with mouse anti-human vimentin and separately with anti
alpha-smooth muscle cell actin (1:200 dilutions) and AlexaFluor-594 (Molecular Probes,
Eugene, OR) tagged secondary antibody for immunofluorescence detection. Porcine
valvular interstitial cells (VICs) were also stained for comparison.

7.3

Results

7.3.1 Cell seeding of Spongy Scaffolds
The overall goal of this project is to assemble a tri-layered construct to mimic the
ultrastructure of the native heart valve. The viability and adaptability of the tri-layered
construct is contingent on the viability of the cells incorporated into the construct (see
Figure 7.1). Therefore, we tested several methods of introducing stem cells into the
spongiosa layer. The first of which, injection of hBMSCs into the spongiosa layer after
the spongy scaffold has been inserted between the fibrous scaffolds, yielded few viable
cells upon removal of the spongiosa layer after 24 hour dynamic functionality testing of
the entire construct and evaluation by Live/Dead (data not shown).
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Figure 7.1: Schematic of the tri-layered construct with location of introduced stem cells.

The second method of cell seeding involved the pre-incubation of the spongy
scaffolds with hBMSCs and inserting of the pre-seeded spongy scaffold between the two
fibrous scaffolds. This yielded more viable cells (see section 7.3.2 below for cell viability
results) and is thus the method that was chosen.
To summarize the procedure of valve assembly and spongiosa insertion, fibrous
scaffolds were dried onto molds and PGG treated. The valve-shape constructs were then
assembled by overlapping two identical fibrous scaffolds using BTglue and sutures
placed at the level of valve wall, sinuses and cusp insertion points. Stem cell-seeded
spongiosa scaffolds (arrow in Figure 7.2c) were inserted between the fibrous scaffolds
inside the cusp structure and edges sealed with BTglue. Finally, the entire construct was
sutured inside the original aortic root from which the mold was cast.

169

Figure 7.2: Valve-shape constructs (a, b, c in (A) denotes individual leaflets) were
assembled by overlapping two identical fibrous scaffolds (B) using BTglue and sutures
placed at the level of valve wall, sinuses and cusp insertion points (C). Stem cell-seeded
spongiosa scaffolds (E-arrow) were inserted between the fibrous scaffolds inside the cusp
structure and edges sealed with BTglue. (F) The construct was sutured inside the original
aortic root from which the mold was cast (G).
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Functionality testing of the tri-layered construct yielded fair results. After 2 days of
conditioning in sterile culture media, one cusp (a) had to be excised due to a superfluous
amount of tissue that impeded the opening and closing of the construct (Figure 7.3,C),
after which the bi-leaflet construct opened and closed more normally. This highlights
the need for more investigation into the assembly process (see Recommendations for
Future Work).

Figure 7.3: Initial functionality testing of the valves in a pulsatile bioreactor; aortic view
(A and B), with a, b, c – the three leaflets. Stem cell-seeded tissue engineered valve
being subjected to bioreactor conditioning in sterile cell culture media (red) (C and D).
External diameter of the porcine valve used in this study was about 23 mm.
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7.3.2 Cell seeded tri-layered construct bioreactor conditioning
A short-term bioreactor study, in which the pulmonary artery scaffolds were
seeded with hBMSCs, revealed that the seeding procedure for the spongiosa and
subsequent insertion into a “sandwich” construct did not affect cell survival after 3 days
while supported signs of stem cell differentiation (data not shown) . After 8 days in the
heart valve bioreactor, cell viability was maintained at more than 90% and hBMSCs
elongated significantly and stained positive for vimentin, but very weak for alpha-smooth
muscle cell actin. Although absolute clear markers for VICs are still a matter of debate,
this staining pattern is indicative of non-activated, quiescent VICs [8] (Figure . Static
controls were also alive, but cells did not elongate and stained very weakly for vimentin
and actin (Figure 7 9).

Figure 7.4 Control VICs stained for actin (A-C) and vimentin (D) (both red, with
overlapped DAPI blue nuclear stain). Bar are 100 m.
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Stem cells retrieved from the bioreactor shared similarities to native VICs, indicating that
physiologic mechanical stimuli offered by our 3D tissue engineered heart valve
constructs and the bioreactor encouraged differentiation of stem cells into VIC-like cells,
a much sought-after outcome of valvular tissue engineering. Moreover, these results were
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Figure 7.5 Bioreactor results with stem cell-seeded valves after 8 days. Cell viability was
confirmed using Live/Dead stain (live cells green, dead cells red) in(A). (B) shows DAPI
nuclear staining confirming presence of cells. (C-D) show immunofluorescence staining
(red, with overlapped DAPI blue nuclear stain) showing elongated, vimentin positive
cells. Bars are 100 m.

obtained within constructs made from collagen scaffolds that would resist physiologic
pressure immediately after implantation.

Figure 7.6 Cell viability (A) and DAPI staining (B) in static controls.
Immunofluorescence staining showing very few vimentin-positive cells (C and D). Bars
are 100 m.
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7.4

Discussion
Our vision of a potential translational scenario using stabilized collagen scaffolds

and autologous stem cells involves the following steps. After initial diagnosis and
collection of mesenchymal stem cells from the patient, imaging of the diseased heart
valve would

provide anatomical coordinates for reconstruction of the heart valve

geometry into solid molds using appropriate software and hardware. Concomitant with
stem cell isolation, valves will be made from decellularized collagen scaffolds by
assembly into tri-layered constructs and then cusps seeded with autologous stem cells as
described in the current study. After conditioning in bioreactors for 1-2 weeks for stem
cell pre-differentiation into VIC-like cells, the patient-tailored engineered heart
valve would be surgically implanted.
Our working premise is that the extracellular matrix of cardiovascular tissues
provides ideal scaffolds for valvular tissue engineering.

Previously we described

development of collagen scaffolds to be used as the fibrous layers of the heart
valve cusps [14] and a scaffold to be used as a spongiosa layer for heart valve tissue
engineering. When the spongy scaffold is seeded with cells and conditioned in
bioreactors, such scaffold-enclosed “cell pockets” maintained cell viability and allowed
transmission of mechanical cues to induce stem cells differentiation into VIC-like cells.
However, with differentiation of the stem cells into VIC-like cells, and remodeling of the
scaffold, the problem of overproduction and continued growth of the valve is possible
[15]. The patient would have to be monitored for valve hypertrophy, whereas to mitigate
this occurrence, growth factors may need to be incorporated into the scaffold, with the
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dosage, release, and duration optimized for a balance between tissue growth and
remodeling. To ascertain the extent of valve growth, accelerated aging tests must be
preformed, whereby in vitro bioreactor studies in conjunction with growth factor studies
could elucidate how the valve will remodel and possibly grow as it ages.

7.5

Conclusions
This study is a stepping stone towards development of a novel approach to

heart valve tissue engineering. The scaffolds we have previously developed were
assembled into anatomically analogous 3-D heart valve shapes using novel proteinbased glue, seeded with stem cells and conditioned in bioreactors to induce stem cell
differentiation. It can be concluded that histiologically similar mechanical stimuli offered
by our TEHV encourages differentiation of stem cells into activated valvular interstitial
cells.
While many aspects and details need to be optimized as far as scaffold assembly
and animal testing are concerned, this approach appears promising for our envisioned
translational scenario.
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CHAPTER 8
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK

8.1

Conclusions
Tissue engineering, the emerging science of combining scaffolds, cells and

specific mechanical and biochemical signals is feasible and holds great promise for
treatment of heart valve disease [1, 2]. Recognizing the vital importance of the three
leaflet layers [3], the outstanding hemodynamics of natural valve homografts [4] and the
need for reconstruction of the physiologic valve design, we hypothesize that combination
of four elements can be utilized for tissue engineering of the “ideal” aortic heart valve: A)
Constructs made from partially stabilized collagenous scaffolds, B) Anatomically
analogous 3-D heart valve shapes made from tri-layered structures that mimic the native
heart valve histo-architecture, C) Autologous multipotent bone marrow derived stem cells
for repopulation and remodeling. These ideas were tested in the work presented here,
allowing us to draw the following conclusions:


We could successfully decellularize pericardium and pulmonary arteries to yield
pure, porous, collagenous scaffolds



Scaffold fixation with PGG:
o Partially stabilized the fibrous collagen scaffolds
o Allowed for cell infiltration in vivo



Scaffold adherence with BTglue showed that:
o Our novel glue was able to adhere the scaffold together
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o Was non toxic to cells


Molding of native aortic heart valves with liquid silicone was:
o Able to duplicate the shape and fine corrugations of the individual leaflets
o Served as a platform on which the collagenous scaffolds could be molded
o The formed collagenous scaffolds could be combined to form a tri-layered
construct that mimics the native histo-architecture of an aortic heart valve
o The formed valve construct functioned comparably to a native aortic valve
during bioreactor testing



Bioreactor testing of stem cell-seeded tri-layered scaffolds
o Supported cell growth and survival
o May possibly support stem cell differentiation into valvular interstitial-like
cells

Therefore, our tissue engineered heart valve replacement approaches hold promise to
create a living heart valve that can potentially grow with the patient.

8.2

Recommendations for Future Work
As this project is still in its early stages, there is much work to be done to

optimize the entire process. At each step in the process there are aspects that must be
investigated in order to make this a viable process that may be utilized in a clinical
setting.
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1) The use of a fibrous scaffold with elastin (not removing the elastin from the
pericardium during the scaffold preparation process is one possibility) can be
investigated for the use of the ventricularis.
2) The glycosaminoglycan (GAG) content should be evaluated in the fibrous scaffolds.
3) The GAG content in the sponsiosa must be augmented to better approximate the
GAG content in the native aortic valve.
4) In terms of the fixation process, a better balance must be established between cell
toxicity, stability, and degradation afforded by PGG cross-linking.
a) In addition, another cross-linking chemical should be evaluated (such as N-(3dimethylaminopropyl)-Nethylcarbodiimide (EDC)) to augment PGG and aid in
better establishing this balance
5) In terms of gluing:
a) Alternative polymerizing agents (other than Glut) can be investigated that could
minimize the deleterious effects of Glut.
b) If Glut is still utilized, the neutralization process should be improved to minimize
the calcification caused by Glut.
c) The elasticity of the glue should be increased to better match the scaffold
properties and thus decrease stresses placed of the scaffold due to the glue.
6) In terms of the molding and assembly process:
a) A computer aided system should be utilized to form the 3-D rendering of the
aortic valve that may be used for molding of the tissue scaffolds
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b) A rapid prototyping interface should be implemented to process the solid molds
(this will replace the silicone molding, that cannot be utilized in a clinical setting)
c) How the valve is assembled, considering how much tissue is used for the leaflets
must be addressed.
d) Dr. Ivan Vesely maintains that a precise central gap is key to valve function [5],
therefore amount of tissue used, suture positions, glue amounts, and leaflet
orientation is key.
e) Optimizing BTglue adhering locations must also be evaluated and perfected, by
assessing how much BTglue to use, where it should be applied (at edges of cusps,
at junction of leaflet and aortic arch), and application procedures (when in the
assembly process to apply BTglue).
f) Once the valve leaflets are constructed, a mechanism by which the valve construct
can be mounted must be tested and perfected, by which either mounting rings,
stents, or direct mounting either with sutures, BTglue, or a combination of the
two should be evaluated.
7) For stem cell seeding and differentiation,
a) Different sources for stem cells should be investigated (such as adipose-derived
stem cells)
b) Biochemical and further mechanical factors should be implemented that influence
differentiation
c) Fundamental studies on native VICs should be performed to establish a standard
by which the cells we use for seeding should be compared.

182

8) In further bioreactor studies,
a) Long-term

bioreactor experiments should be performed to evaluate the

mechanics of the valve over time, as well as stem cell differentiation and
remodeling potential of our scaffolds
b) The interface between the surface of the scaffold and blood should be addressed,
whereby the physical and chemical structure of the surface is ascertained via
atomic force microscopy(AFM) studies, and bioreactor functionality studies
whereby the fluid environment around the construct is more closely representative
of the in vivo environment in which it will be implanted to assess hemolysis and
thrombogenicity
c) The valve must be endothelialized, to mimic the surface characteristics of a native
valve and potentially alleviate hemolytic and thrombogenic problems associated
with blood/biomaterial interactions
9) Once these points are addressed, large animal studies (preferably primate
implantation) should be performed that follows our proposed translational clinical
scenario:
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Figure 8.1: Translational Scenario for Patient-Tailored Heart Valve Tissue Engineering

Overall, this translational scenario will cost no more than the currently available
bioprosthetic heart valve, which currently range from anywhere between $5,000 and
$20,000 [6]. High initial costs will include the imaging software and the rapid
prototyping machine for steriolithography for actual manufacturing. The highest
recurring costs for each patient will be the CT scans for imaging, but even current
patients receiving a valve replacement necessitate scans. All other aspects of the process
will incur will monetary requirements, while the benefits of receiving a patient-tailored
valve will be innumerable.
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